Official Title: ATopi[INVESTIGATOR_393556] 2 (TRuE-AD2)
A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study
of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and
Adults With Atopic Dermatitis
Study ID: [REMOVED]
Document Date: 13 FEB 2019
Incyte Co1poration 
Protocol INCB [ZIP_CODE]-304 Am 2 Version 2 
Clinical Study Protocol 
INCB [ZIP_CODE]-304 Page 1 of88 
13 FEB 2019 
Iopi[INVESTIGATOR_393557] E,valuation in ,Atopi[INVESTIGATOR_393558]!ermatitis Study 1, 
(TRuE-AD2) 
A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled 
Efficacy and Safety Study ofRuxolitinib Cream Followed by a 
Long-T erm Safety Extension Period in Adolescents and Adults With 
Atopic Dermatitis 
Product: Ruxolitinib Cream 
IND Number: -
EudraCT Number: 2018-003713-18 
Phase of Study: 3 
Sponsor: Incyte Corporation 
1801 Augustine Cut-Off 
Wilmington, DE [ZIP_CODE] 
Original Protocol (Version 0): 01 NOV 2018 
Amendment (Version) 1: 22 JAN 2019 
Amendment (Version) 2: [ADDRESS_675404] their origin in the Declaration of 
Helsinki and conducted in adherence to the study Protocol, applicable Good Clinical Practices, and applicable laws 
and country-specific regulations in which the study is being conducted. 
The infonnation in this document is confidential. No pait of this infonnation may be duplicated, referenced, or 
transmitted in any fonn or by [CONTACT_61076] (electronic, mechanical, photocopy, recording, or otherwise) v.iithout prior 
written consent. 
CONFIDENTIAL 
Incyte Corporation  Page 2 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB 2019  
CONFIDENTIAL  INVESTIGATOR' S AGREEMENT  
I have read the INCB [ZIP_CODE]-304 Protocol Amendment 2 (Version 2 dated 13 FEB  2019 ) and  
agree to cond uct the study as outlined.  I agree to maintain the confidentiality of all information 
received or developed in connection with this Protocol. 
(P
rinted Name [CONTACT_7919]) 
(S
ignature of Investigator)  (D
ate) 

Incyte Corporation  Page [ADDRESS_675405] OF ABBREVIATION S ..........................................................................................................8  
1. PROTOCOL SUMMARY ..........................................................................................11  
2. INTRODUCTION  ......................................................................................................20  
2.1. Background .................................................................................................................20  
2.1.1.  Atopic Dermatitis  ........................................................................................................20  
2.1.2.  Diagnosis of Atopic Dermatitis  ..................................................................................20  
2.1.3.  Current Treatment and Unmet Needs for Atopic Dermatitis  ......................................21  
2.1.4.  Role of Janus Kinases in Atopic Dermatitis  ...............................................................22  
2.2. Ruxolitinib  ..................................................................................................................22  
2.2.1.  Oral Ruxolitinib  ..........................................................................................................22  
2.2.2.  Ruxolitinib Cream  ......................................................................................................23  
[IP_ADDRESS].  Preclinical Drug Disposition Summary  ......................................................................23  
[IP_ADDRESS].  Preclinical Safety  ........................................................................................................24  
[IP_ADDRESS].  Clinical Safety  ............................................................................................................24  
[IP_ADDRESS].  Efficacy of Ruxolitinib Cream  ....................................................................................25  
2.3. Study Rationale  ...........................................................................................................28  
2.3.1.  Scientific Rationale for Study Design  ........................................................................28  
2.3.2.  Justification for Selected Treatment Regimen  ............................................................29  
2.4. Benefit/Risk Assessment  ............................................................................................30  
3. OBJECTIVES AND ENDPO INT S ............................................................................32  
4. STUDY DESIGN  .......................................................................................................34  
4.1. Overall Design  ............................................................................................................34  
4.2. Overall Study Duration  ...............................................................................................35  
4.3. Study Termination  ......................................................................................................35  
5. STUDY POPULATION  .............................................................................................36  
5.1. Inclusion Criteria  ........................................................................................................36  
5.2. Exclusion Criteria  .......................................................................................................37  
5.3. Lifestyle Considerations .............................................................................................39  
5.4. Screen Failures  ............................................................................................................39  
5.5. Replacement of Participants  .......................................................................................39  
6. STUDY TREATMENT  ..............................................................................................40  

Incyte Corporation  Page 4 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB 2019  
CONFIDENTIAL  6.1. Study Treatment Administered  ...................................................................................40  
6.2. Preparation, Handling, and Accountability ................................................................41  
6.3. Measures to Minimize Bias:  Randomization and  Blinding .......................................42  
6.4. Study Treatment Compliance  .....................................................................................42  
6.5. Modifications to Treatment Regimen  .........................................................................43  
6.5.1.  Criteria and Procedures for Application Interruptions of Study Drug .......................43  
6.5.2.  Criteria for Permanent Discontinuation of Study Drug Due to an Adverse 
Event ...........................................................................................................................44  
6.6. Concomitant Medications and Procedures .................................................................45  
6.6.1.  Permitted Medications and Procedures ......................................................................45  
6.6.2.  Restr icted Medications and Procedures ......................................................................45  
6.6.3.  Prohibited Medications and Procedures .....................................................................46  
6.7. Treatment After the End of the Study .........................................................................46  
7. DISCONTINUATION OF STUDY TREATMENT AND PARTICIPANTDI
SCONTINUATION/WITHDRAWAL  ..................................................................[ADDRESS_675406] to Follow- Up.......................................................................................................48  
8. STUDY ASSESSMENTS AND PROCEDURES  ......................................................49  
8.1. Administrative and General Procedures .....................................................................49  
8.1.1.  Informed Consent Form Process  ................................................................................49  
8.1.2.  Screening Procedures  ..................................................................................................50  
8.1.3.  Interactive Response Technology Procedure ..............................................................50  
8.1.4.  Distribution of Study Reminder Cards and Diaries ....................................................51  
8.1.5.  Demography and Medical History ..............................................................................51  
[IP_ADDRESS].  Demographics and General Medical History  .............................................................51  
[IP_ADDRESS].  Medical and Treatment History  ..................................................................................51  
8.2. Efficacy Assessments  .................................................................................................52  
8.2.1.  Investigator's Global Assessment ...............................................................................52  
8.2.2.  Eczema Area and Severity Index Score ......................................................................52  
8.2.3.  SCORing Atopic Dermatitis  .......................................................................................53  

Incyte Corporation  Page 5 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB 2019  
CONFIDENTIAL  8.2.4.  Target Lesion Assessment  ..........................................................................................53  
8.2.5.  Body Surface Area  ......................................................................................................54  
8.2.6.  Photography ................................................................................................................54  
8.2.7.  Patient -Reported Outcomes  ........................................................................................54  
[IP_ADDRESS].  Dermatology Life Quality Index  ................................................................................55  
[IP_ADDRESS].  Patient Global Impression of Change .........................................................................56  
[IP_ADDRESS].  Patient -Oriented Eczema Measure  .............................................................................56  
[IP_ADDRESS].  EQ-5D- 5L ...................................................................................................................56  
[IP_ADDRESS].  Work Productivity and Activity Impairment Questionnaire:  Specific Health 
Problem Ver sion 2.0 ...................................................................................................57  
[IP_ADDRESS].  Itch Numerical Rating Scale  .......................................................................................57  
[IP_ADDRESS].  Skin Pain Numerical Rating Scale  ..............................................................................57  
[IP_ADDRESS].  PROMIS Sleep Questionnaires:  Short Form – Sleep -Related Impairment 
(8a) and Short Form – Sleep Disturbance (8b)  ...........................................................57  
8.2.8.  Health Economics  .......................................................................................................58  
8.3. Safety Assessments  .....................................................................................................58  
8.3.1.  Adverse Events  ...........................................................................................................59  
8.3.2.  Physical Examinations  ................................................................................................59  
8.3.3.  Vital Signs  ..................................................................................................................60  
8.3.4.  Electrocardiograms  .....................................................................................................60  
8.3.5.  Laboratory Assessments  .............................................................................................60  
[IP_ADDRESS].  Pregnancy Testing  ......................................................................................................61  
[IP_ADDRESS].  Serology ......................................................................................................................61  
8.4. Pharmacokinetic Assessments  ....................................................................................62  
8.6. Unscheduled Visits .....................................................................................................63  
8.7. End of Treatment and/or Early Termination ..............................................................63  
8.8. Safety Follow -Up ........................................................................................................64  

Incyte Corporation   Page 6 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB 2019  
CONFIDENTIAL  9. ADVERSE EVENTS:  DEF INITIONS AND PROCEDURES FOR 
RECORDING, EVALUATING, FOLLOW -UP, AND REPORTING  ......................64  
9.1. Definition of Adverse Event .......................................................................................64  
9.2. Definition of Serious Adverse Event ..........................................................................65  
9.3. Recording and Follow-Up of Adverse Events and/or Serious Adverse Events .........[ADDRESS_675407] OF TABLES  
Table 1:  Primary and Key Secondary Objectives and Endpoints .............................................11  
Table 2:  Key Study Design Elements  .......................................................................................12  
Table 3:  Schedule of Activities:  Vehicle -Controlled Period ...................................................14  
Table 4:  Schedule of Activities:  Long -Term Safety Extension Period ....................................17  
Table 5:  Objectives and Endpoints ...........................................................................................32  
Table 6:  Study Treatment Information  .....................................................................................41  
Table 7:  Guidelines for Interruption and Restarting of Study Drug .........................................44  
Table 8:  Investigator's Global Assessment ...............................................................................52  
Table 9:  Required Laboratory Analytes  ....................................................................................61  
Table 10:  Populations for Analysis .............................................................................................[ADDRESS_675408] OF FIGURES  
Figure  1: Study Design Schema  .................................................................................................13  
Figure  2: Stepwise Approach to the Management of Atopic Dermatitis  ...................................21  
Figure  3: INCB [ZIP_CODE]-206 Study Schema ................................................................................26  
Figure  4: Control of the Overall Type I Error Rate ....................................................................[ADDRESS_675409]  aspartate aminotransferase  
BID twice daily  
BSA body surface area 
BSA assessment – Palmar 
method 1% BSA for each participant is approximately equal to the surface of their palm plus 5 digits; handprint may be used interchangeably 
CFR Code of Federal Regulations 
Cmax Maximal plasma concentration  
CDLQI  Children Dermatology Life Quality Index 
CTCAE  Common Terminology Criteria for Adverse Events 
DLQI  Dermatology Lif e Quality Index  
EASI  Eczema Area and Severity Index  
EASI50  ≥50% improv ement in EASI score 
EASI75  ≥75% improvement in EASI score  
EASI90  ≥90% improvement in EASI score  
ECG  electrocardiogram  
eCRF  electronic case report form  
EOT  end of treatment   
EQ-5D-5L EQ-5D is a validated, self -administered, generic, utility questionna ire 
wherein participants will rate their current health state based on the following criteria:  mobility, self- care, usual activities, pain/discomfort, and 
anxiety/depression. 
ET early termination  
FDA Food and Drug Administration 
flare an epi[INVESTIGATOR_393559], such that it requires 
re-initiation or escalation of treatment (IGA of at least 2)  
GCP  Good Clinical Practice  
HDL  high-density lipoprotein 
HIV human immunodeficiency virus 
HIPAA  Health Insurance Portability and Accountability Act of 1996 

Incyte Corporation   Page 9 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB 2019  
CONFIDENTIAL  Abbreviations and 
Special Terms  Definition  
IB Investigator 's Brochure 
ICF informed consent form  
ICH International Council on Harmonization of Technical Requirements for 
Registration of Pharmaceuticals for Human Use  
IEC independent ethics committee  
IGA Investigator 's Global Assessment  
IGA-TS Investigator 's Global A ssessment  Treatment Success ( IGA score of 0 or 1 
with ≥ 2 grade improvement from baseline)  
IL interleukin  
IRB institutional review board  
IRT interactive response technology  
Itch NRS  Itch Numerical Rating Scale 
ITT intent -to-treat 
JAK Janus kinase  
LDL  low-density lipoprotein  
LL lower limbs  
LPLV  last participant last visit  
LTS long- term safety  
MedDRA  Medical Dictionary for Regulatory Activities  
ni. non-inferiority  
NOAEL  no-observed -adverse- effect level  
PASI  Psoriasis Area Severity Index  
PD pharmacodynamic  
PDE  phosphodiesterase 
PGA Physici an's Global Assessment  
PGIC  Patient Global Impression of Change  
PK pharmacokinetic  
POEM  Patient -Oriented Eczema Measure  
PP per Protocol 
PROMIS® Patient -Reported Outcomes Measurement Information System  
QD once daily  
RNA  ribonucleic acid  
SAE  serious adverse event  
SCORAD  SCORing Atopic Dermatitis – tool used to assess extent and severity  
(intensity)  of eczema  
Skin Pain NRS  Skin Pa in Numerical Rating Scale  

Incyte Corporation   Page [ADDRESS_675410] upper limit of normal 
VC vehicle-control 
VHP  Voluntary Harmonisation Procedure 
WPAI: SHP v2.0 Work Productivity and Activity Impairment Questionnaire:  Specific Health Problem Version 2.0 

Incyte Corporation  Page 11 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB 2019  
CONFIDENTIAL  1. PROTOCOL SUMMARY
Protocol Title:   Topi[INVESTIGATOR_520702] A topic  Dermatitis Study 2 (TRuE -AD2 ) 
A Phase 3, Double-Blind, Randomized, 8- Week , Vehicle-Control led Efficacy and  Safety Study 
of Ruxolitinib Cream Followed by a Long- Term Safety Extension P eriod in Adolescents and 
Adults With Atopic Dermatitis  
Protocol Number:   INCB [ZIP_CODE]-304 
Objectives and Endpoints :  Table 1 presents the primary and key secondary endpoints and 
objectives . 
Table 1: Primary and Key Secondary Objectives and Endpoints  
Objectives Endpoints  
Primary  
To establish the efficacy of ruxolitinib cream in 
participants with AD . •Proportion of participants achieving IGA -TS at
Week  8
Key Secondary  
To further assess efficacy of ruxolitinib cream . •Proportion of participants who achieve EASI 75 at
Week 8.
•Proportion of participants with a ≥  4-point
improvement in Itch NRS  score from baseline to
Week 8.
•Proportion of participants with a clinically
meaningful improvement in t he PROMIS Short
Form – Sleep  Disturbance (8b) 24-hour recall  score
at W eek 8.
Overall Design  
Table [ADDRESS_675411]. 

Incyte Corporation  Page 12 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB 2019  
CONFIDENTIAL  Table 2: Key Study Design Elements  
Study Phase  Phase 3  
Clinical Indication  Atopic Dermatitis  
Population  Adolescent s aged ≥ 12 to 17 years, inclusive, and men and women aged 
≥ [ADDRESS_675412]  2 years duration, an 
IGA score of 2  to 3, and %BSA involvement (excluding scalp) of 3% to 20%.  
Number of 
Participants  Approximately 600 participants  
Study Design  Randomized  (2:2:1) , double -blind , 8-week VC period  followed by a  
randomized, double-blind, 44- week LTS extension period.  In the LTS  period, 
participants initially randomized to vehicle  will receive either ruxolitinib 0.75% 
or 1.5 % cream .   
Estimated Duration 
of Study Participation  Screening:  up to 28 days  
Vehicle -control led period:  8 weeks 
Double-blind, r andomized LTS period:  44 weeks 
Follow-up:  30 (+ 7) days after last application of study drug or last visit  
Total:  u p to 60 weeks  
DSMB/DMC  No 
Treat ment Groups and Duration:  
Adolescents  aged ≥ 12 to 17 years, inclusive, and men and women aged ≥ [ADDRESS_675413] 2 years  duration, an IGA score of 
2 to 3, and % BSA involvement of 3% to 20% (excluding scalp) will be enrolled  and receive 
treatment with ruxolitinib  0.75% cream  BID, ruxolitinib 1.5% cream BID , or vehicle cream  in a 
2:2:1 randomization for a total duration of 8 weeks (with a screening period of approximately 
28 days ) during the VC  period of the study.  Adolescents will make up approximately 20% of the 
overall study population. 
At Week 8,  all participants who successfully complete the VC  period of the study and all Week  8 
assessments will be offered participation  in the LTS treatment period with ruxolitinib 0.75% or 
1.5% cream BID.  The required %BSA range and IGA score entry into the LTS period is 0 % to 
20% and 0 to 4 grade, respectively.  Participants who were initially treated with either ruxolitinib 
0.75% or 1.5% cream will remain in their respective treatment regimen, while thos e participants 
who were initially treated with vehicle will be randomized to either ruxolitinib 0.75% or 1.5% 
cream BID.  During this LTS period, participants w ill have study visits every 4  weeks until the 
end of the study (52 weeks total). 
After the Week 8 visit,  during the LTS period, participants will self -evaluate recurrence of AD 
and will treat those areas of the skin with active AD changes (not to exceed up to 20% BSA).  If 
lesions clear between study visits, participants will stop treatment application [ADDRESS_675414] follow -up assessme nts 
30 (+ 7) days after the last application of study drug.  

Incyte Corporation   Page 14 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB 2019  
CONFIDENTIAL  Table 3: Schedule of A ctivitie s:  Vehicle-Control led Period  
Visit Day (Range)  Screen ing Vehicle -Controlled Treatment  Notes  
Days  
-28 to -1 Day 1 
(Baseline)  Week 2  
(± 3 d)  Week 4  
(± 3 d)  Week 8 */EOT  
(± 3 d)  *All assessments for the Week [ADDRESS_675415] be performed before 
participants may enter the LTS 
period.  
Administrative p rocedures  
Informed consent (including assent)  X      
Contact [CONTACT_12067]  X X X X X  
Inclusion/exclusion criteria review  X X     
Demography  and general and disease 
medical history  X      
Prior/concomitant medications  X X X X X  
Apply study drug   X X X X 1st AM application  under site 
supervision.  
Weigh/dispense or re-dispense study drug 
and distribute study drug diary and 
reminder card  X X X X Used tubes will be replenished , and 
unused tubes may be re -dispensed. 
Collect /weigh  study drug and 
collect/ review study drug diar y   X X X  
Assess compliance   X X X X  
Safety a ssessments  
AE assessments and targeted physical 
exam inations  X X X X X Body systems with symptoms 
should be physically examined.  
Ad hoc photography of skin-related 
AEs should also occur as applicable . 
Comp rehensive physical examination  X    X  
Vital signs /body weight /height  X* X X X X* *Height and weight at screening  and 
Week 8 .  
12-lead ECG  X     12-lead ECG performed within 
2 months before baseline is 
acceptable.  

Incyte Corporation   Page 15 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB 2019  
CONFIDENTIAL  Table 3: Sched ule of Activities:  Vehicle -Controlled Period  (Continued)  
Visit Day (Range)  Screening  Vehicle -Controlled Treatment  Notes  
Days  
-28 to -1 Day 1 
(Baseline)  Week 2  
(± 3 d)  Week 4  
(± 3 d)  Week 8 */EOT  
(± 3 d)  *All assessments for the Week [ADDRESS_675416] be perf ormed before participants 
may enter the LTS period.  
Efficacy assessments  
Evaluate %BSA affected by [CONTACT_393595]  X X X X X* *At Week 8, t o qualify for LTS period , 
the %BSA range is 0 % to ≤ 20%.  
Target lesion  X X* X X X *A lesion of ≥  10 cm2 needs to be 
identified  at baseline (excluding the 
hands, feet and genitalia)  
Photography (target lesion  close -up/ 
regional  body area)   X X X X Ad hoc photography (at selected sites) of 
skin-related AEs  is recommended . 
EASI  X X X X X  
SCORAD   X X X X  
IGA X X X X X* *At Week 8, t o qualify for LTS period , 
the IGA range is [ADDRESS_675417] application of study 
drug in the vehicle -controlled period.   
Skin Pain NRS   
Patient-reported o utcome questionnaires  – to be evaluated prior to any other study procedures/assessments; see Section  8.2.7 
DLQI /CDLQI   X X X X  
PGIC    X X X  
POEM   X X X X  
EQ-5D-5L questionnaire  X X X X X  
WPAI:SHP questionnaire  X X X X X  
PROM IS sleep questionnaire s (24-hour 
recall)  Diary is completed daily  from screening through the last application of study drug in the 
vehicle-controlled period.  PROMIS Short Form – Sleep -Related 
Impairment  (8a) collected in the evening 
before  sleepi[INVESTIGATOR_007] . 
PROMIS  Short Form – Sleep Disturbance 
(8b) collected in the morning after the 
participant wakes up . 
PROMIS sleep questionnaires (7 -day 
recall)      X PROMIS Short Form – Sleep -Related 
(8a) and  Short Form – Sleep -Disturbance 
(8b) will be completed at Week 8  (this 
will b e the baseline assessment for the 
7-day recall  questionnaires , collected 
during the Week 8 study visit ). 

Incyte Corporation   Page 16 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB 2019  
CONFIDENTIAL  Table 3: Schedule of Activities:  Vehicle- Controlled Period  (Continued)  
Visit Day (Range)  Screening  Vehicle -Controlled  Treatment  Notes  
Days  
-28 to -1 Day 1 
(Baseline)  Week 2  
(± 3 d)  Week 4  
(± 3 d)  Week 8 */EOT  
(± 3 d)  *All assessments for the Week [ADDRESS_675418] be performed before the in -clinic study 
drug application.   
Serum chemistries  X X X X X  
Hematology  X X X X X  
Serology  X*     *HIV antibody.  
Pregnancy testing  X* X X X X *Female participants of childbearing 
potential will have a serum  test at screening 
and follow -up and a urine test at all other 
visits.  A positive urine test must be 
confirmed by a serum test.  
FSH level  X     For confirmation of nonchildbearing status 
of women who are postmenopausal defined 
as amenorrhea at least 12 m onths before 
screening.  
Urinalysis  X      
PK plasma sampling (trough)    X X X Time of last study drug application to be 
written in eCRF.  
Blood samples must not be drawn from the 
area that has been treated with study drug.  

Incyte Corporation   Page 17 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB 2019  
CONFIDENTIAL  Table 4: Sched ule of Activities:   Long- Term Safety Extension Period  
Visit Day (Range)  LTS Extension Treatment  Follow -Up 
Notes  Week 12  
(±7 d)  Weeks 16, 
20, and 24  
(±7 d)  Weeks 28, 
32, and 36  
(±7 d)  Weeks 40, 
44, and 48  
(±7 d)  Week 52 
ET/EOT 
(±7 d)  Unscheduled 
Visits  30 (+7) days 
After Last Dose 
of Study Drug  
Administrative procedures  
Contact [CONTACT_12067]  X X X X X X X  
Prior/concomitant medications  X X X X X X X  
Apply study drug  X X X X X   1st AM application under 
site supervision.  
Weigh/dispense or re -dispense study 
drug and distribute study drug diary 
and reminder card  X X X X  X  Used tubes will be 
replenished and unused 
tubes may be re -dispensed  
Collect /weigh  study drug and 
collect/ review study drug diary  X X X X X X   
Capture start and end date of a 
treatment cy cle X X X X X X X The start/end -date will be 
captured by [CONTACT_2299].   
The end date of a treatment 
cycle will be +3  days after 
lesions clear.  
Refer to  Study Manual . 
Safety assessments  
AE assessments  and targeted physical 
examinations  X X X X X X X Body systems with 
symptoms should be 
physically examined.  
Ad hoc photography of 
skin-related AEs  should 
also occur as applicable . 
Comprehensive physical examination      X    
Vital signs/body weight/height  X X* X X X* X X *Height and weight at 
Week s 24 and  52/EOT.  
Efficacy assessments  
Evaluate %BSA affected by [CONTACT_393596] X X X X X X X Participants may only treat 
up to 20%  BSA . 
IGA X X X X X X X  

Incyte Corporation   Page 18 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB 2019  
CONFIDENTIAL  Table 4: Schedule of Activities:  Long -Term Safety Extension Period  (Continued)  
Visit Day (Range)  LTS Extension Treatment  Follow -Up 
Notes  Week 12  
(±7 d)  Weeks 16, 
20, and 24  
(±7 d)  Weeks 28, 
32, and 36  
(±7 d)  Weeks 40, 
44, and 48  
(±7 d)  Week 52 
ET/EOT 
(±7 d)  Unscheduled 
Visits  30 (+7) days 
After Last Dose 
of Study Drug  
Patient -report ed outcome questionnaires  – to be evaluated prior to any other study procedures/assessments; see Section  8.2.7   
DLQI /CDLQI  X X*   X X X *At Week 24 only.  
POEM  X X*   X X X *At Week 24 only.  
EQ-5D-5L questionna ire X X* X*  X  X *At Weeks 24 and  36 only  
WPAI:SHP questionnaire  X X* X*  X  X *At Weeks 24 and  36 only.  
PROMIS sleep questionnaire s (7-day 
recall)  X X*   X   *At Week  24 only.  
PROMIS Short Form –   
Sleep -Related Impairment  
(8a). 
PROMIS Short Form – 
Sleep Disturbance (8b). 
Note:   Recall  period 
changed from past [ADDRESS_675419] be performed before the in-clinic study drug application.   
Serum chemistries  X X X X X X X  
Hematology  X X X X X X X  
Pregnancy testing  X X X X X X X* *Female participants of 
childbearing potential will 
have a serum test at 
screening and follow -up 
and a urine test at all other 
visits.  A positive urine test must be confirmed by a serum test.  
PK plasma sampling (trough)  X X X X X X X Time of last study drug 
application to be written in 
eCRF. 
Blood samples must not be 
drawn from the area that has been treated with study 
drug.  

Incyte Corporation   Page 19 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB 2019  
CONFIDENTIAL    

Incyte Corporation   Page 20 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB  2019  
CONFIDENTIAL  2. INTRODUCTION 
Ruxolitinib cream is a topi[INVESTIGATOR_393561], AA, vitiligo, and plaque psoriasis.  Ruxolitinib phosphate is 
an inhibitor of the JAK family of protein tyrosine kinases.  Isogenic and inflammatory cytokines 
are strongly implicated in the pathogenesis of psoriasis, AA, and AD.  Because JAKs serve to translate extracellular signals from a number of relevant cytokines and growth factors 
upregulated in inflammatory diseases such as psoriasis, AA, and AD, JAK inhibitors represent 
potential therapeutic agents for these disease states.  
2.1. Background  
2.1.1. Atopic Dermatitis  
Atopic dermatitis is a chronic, recurring, inflammatory, and itchy skin condition tha t affects 
worldwide up to 25% of children and up to 12% of adults (Eichenfield et al 2014, Hanifin 
et al 2007, Harrop et al 2007, Rönmark et al 2012, Vinding et al 2014).  Its incidence in the 
industrialized countries appears to be increasing, and it is associated with substantial cost 
($3.[ADDRESS_675420] medical costs alone; Ellis  et al 2002).  Although AD is not 
life-threatening, patients with AD are at a higher risk for the development of other potentially 
life-threatening disorders such as asthma and/or food allergy ( Spergel 2010).  This disease 
evolution leading to the possible development of other atopic conditions, including food allergy, 
asthma, and allergic rhinitis, is often termed as " atopic march. " 
According to the recent Global Burden of Disease project, worldwide AD is one of the [ADDRESS_675421] disability ranking of all nonmalignant skin 
diseases ( Hay et al 2014).  
2.1.2. Diagnosis of Atopic Dermatitis 
One of the earliest and most recognized sets of diagnosti c criteria is the Hanifin and Rajka 
criteria, which requires that 3 of 4 criteria and 3 of 23 minor criteria be met ( Purvis 2014).  
Essential features that are present in this disease are pruritus, eczema (acute, subacute, ch ronic), 
chronic or relapsing history, and typi[INVESTIGATOR_73262]- specific patterns, including the 
following: 1) facial, neck, and extensor involvement in infants and children; 2) current or previous flexural lesions in any age group; 3) sparing of the groin and axillary regions. 
The clinical pattern of AD varies with age.  Infants usually show acute erythematous and often 
develop exudative papules on the face or scalp.  The childhood (age 2 years to puberty) and adult 
phases of AD tend to have less acut e or exudative lesions but instead typi[INVESTIGATOR_393562] (flexural folds, the face and neck, the upper arms and back, and 
the dorsa of the hands, feet, fingers, and toes) that represent a more chronic stage of the condition 
(Akdis et al 2006).  The unifying and cardinal feature of all presentations of AD is the 
pronounced and often unbearable itching. 

Incyte Corporation   Page 24 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB  2019  
CONFIDENTIAL  [IP_ADDRESS]. Preclinical Safety  
In animal studies, r uxolitinib cream was not a contact [CONTACT_520709], acute phototoxicity, or photoallergic potential.   Ruxolitinib cream (up 
to 1.5%) applied BID for up to [ADDRESS_675422] been observed along with lymphoid depletion in bone marrow and lymphoid organs.  
Opportunistic infections considered secondary to immune suppression, were noted in dogs.  Systemic exposures in these studies exceeded those anticipated with topi[INVESTIGATOR_59407].  
Ruxolitinib was not teratogenic when administered to pregnant rats or rabbits; there were no 
adverse developmental effects at doses below those associated with maternal toxicity.  Ruxolitinib was not mutagenic in a bacterial mutagenicity assay (Ames test) or clastogenic in 
in vitro  chromosomal aberration assay (cultured human peripheral blood lymphocytes) or in vivo 
in a rat bone marrow micronucleus assay. 
In a toxicity study of orally administered ruxolitinib in juvenile rats beginning on Days 7, 14, or 
21 postpartum, dose-related effects on body weight gain and decrements in various bone 
measures were observed in all cohorts.  Hematology and other microscopic findings were similar to those previously observed in general toxicology studies.  Other than the bone findings, there 
were no other novel toxicities in juvenile animals.  In animals administered ruxolitinib beginning on Day 21 postpartum (considered approximately equivalent to a 2 year old human), bone findings occurred at exposures higher than those anticipated with topi[INVESTIGATOR_59407].  The 
clinical relevance of this study in humans is not clear.  
Please refer to the ruxolitinib cream IB for more details.  
[IP_ADDRESS]. Clinical Safety  
Ruxolitinib is a novel, potent, and selective inhibitor of the JAKs, specifically JAK1 and JAK2 with modest to marked selectivity against TYK2 and JAK3.  Ruxolitinib potently (IC
50 < 5 nM) 
inhibits JAKs, yet it does not significantly inhibit (< 30% inhibition) a broad panel of 26 kinases 
when tested at 200 nM (approximately 100 times the average IC 50 value for JAK enzyme 
inhibition).  Ruxolitinib also potently inhibited the phosphorylation of STAT proteins and the production of proinflammatory factors  induced by [CONTACT_125433]-23 and interferon γ.  
Topi[INVESTIGATOR_520703] -based skin inflammation, the delayed- type hypersensitivity model in mice, including 
reduced ear swelling,  reduced immune cell infiltrates, and normalization of tissue histology.  
Furthermore, ruxolitinib was also efficacious in the inflammatory phase of the dorsal delayed -type hypersensitivity model when applied in a clinically relevant cream formulation.  

Incyte Corporation   Page 30 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB  2019  
CONFIDENTIAL  2.4. Benefit/Risk Assessment  
Ruxolitinib  presents a low risk of cutaneous toxicity both in animals and clinical studies.  
Ruxolitinib  cream tested posit ive in a photoclastogenicity assay; hence, there may be a risk of 
skin reaction to the combined exposure of ruxolitinib and sunlight.  Ruxolitinib cream did not act 
as a contact [CONTACT_520710].  This lack of adverse cutaneous effects has been 
supported by [CONTACT_427450], where cutaneous AEs have been infrequent and of similar 
frequency and severity as with vehicle control treatment.  Participants  should be cautioned to 
avoid excessive exposure to either natural or artificial sunlight (including tanning booths, sun 
lamps, etc).  
The primary clinical risks noted with orally administered ruxolitinib  treatment for polycythemia 
vera or myelofibrosis are  the potential sequelae of decreased hematopoietic proliferation 
secondary to the inhibition of growth factor pathways by [CONTACT_166527]2 antagonism.  Dose-dependent, 
reversible thrombocytopenia has been observed in participants with myelofibrosis, as well as anemia and less frequently neutropenia.  An increased rate of infection is an additional potential 
risk of immunomodulation.  In healthy participants and rheumatoid arthritis participants with 
greater bone marrow reserve, the effects on hematopoietic proliferation appear to be less pronounced.  Ruxolitinib cream has 3% to 5% of the relative systemic availability of oral 
treatment, which was studied in participants with psoriasis.  Owing to its low systemic 
bioavailability, ruxolitinib cream is not expected to bring about clinically significant changes in hematology laboratory investigations.  
The results of the INCB [ZIP_CODE]-206 dose range-finding study in adults with AD are provided and discussed in more detail in Section [IP_ADDRESS].1.  The efficacy outcomes for all treatment groups can be summarized as follows: 
• IGA response and EASI50/75/90 response rates showed all ruxolitinib cream treatment regimens to be efficacious and statistically superior to its vehicle.  
• Efficacy was ti me- and regimen -related, with 1.5% cream QD and 1.5% cream BID 
numerically greater than the other treatment groups, including the active control ( TC 
0.1% cream BID).  
• All ruxolitinib cream strengths continued to demonstrate improvement through 
Week  8. 
• Promp t effect on itch was observed with all active treatment groups within 24 hours 
after study baseline.  
• The therapeutic response to 1.5% ruxolitinib cream BID plateaued after Week 8 (in 
IGA response and mean EASI change; note:  this was the only treatment applied 
continuously for 12 weeks). 
All active treatment groups were found to have no notable AEs  and were well -tolerated on 
application sites.  They were also unremarkable for laboratory values, vital signs, or physical examinations.  

Incyte Corporation   Page [ADDRESS_675423] hematology parameters (red blood cells and platelet counts) were 
noted in the laboratory assessments (primarily on 1.5% cream BID regimen), they were mostly 
within the limits of normal range of values, transient (platelets), asymptomatic, and clinic ally 
insignificant and did not necessitate any remedial action.  
Based on the above information, ruxolitinib up to 1.5% cream BID can be safely used as a 
topi[INVESTIGATOR_393579]- to-risk ratio 
from among those investigated. 
More detailed information can  be found in the ruxolitinib cream IB. 

Incyte Corporation   Page 32 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB  2019  
CONFIDENTIAL  3. OBJECTIVES AND ENDPO INTS  
Table 5 presents the objectives and endpoints. 
Table 5: Objectives and Endpoints  
Objectives  Endpoints  
Primary  
To establish the efficacy of ruxolitinib cream  in participants 
with AD.  • Proportion of participants achieving  IGA-TS at Week  8. 
Key Secondary  
To further as sess the treatment e ffects of ruxolitinib cream.  • Proportion of participants who achieve EASI75  at Week 8 . 
• Proportion of participants with a ≥  4-point  improvement  in 
Itch NRS score from baseline to Week 8 . 
• Proportion of participants  with a clinically meaningful 
improvement in the PROMIS Short Form – Sleep  
Disturbance  (8b – 24-hour recall ) score at Week 8.  
Secondary  
To evaluate the safety an d tolerability of ruxolitinib  cream.  The frequency, duration, and severity of AEs; performing 
physical examinations; collecting vital signs; and collecting 
laboratory data for hematology, serum chemistry, and urinalysis.  
To further evaluate efficacy of ruxolitinib  cream . • Proportion of parti cipants achieving an IGA -TS at Weeks 2 
and 4.  
• Proportion of participants achieving an IGA of 0 or 1  at each 
visit. 
• Proportion of participants with a ≥  4-point improvement in 
Itch NRS score from baseline to Weeks 2 and 4.  
• Proportion of  participants who achieve EASI 50 at each visit 
during the VC period . 
• Proportion of par ticipants who achieve EASI 75 at W eeks 2 
and 4.  
• Proportion of  participants who achieve EASI90  at each visit 
during the VC period.  
• Mean percentage change from baseline in EASI score at each visit during the VC period.  
• Mean percentage change from baseline in SCORAD  score at 
each visit during the  VC period.  
• Change from b aseline in Itch NRS s core at each visit during 
the VC period.  
• Time to achieve Itch NRS  score improvement of at least 2, 
3, or 4 points . 
• Change from baseline in Skin Pain NRS score at each visit 
during the VC period.  
• Proportion of participants  with a clinically meaningful 
impro vement in the PROMIS  Short Form – Sleep -Related 
Impairment  (8a) 24-hour recall  score at Week s 2, 4 , and 8. 
• Change from b aseline in PROMIS Short Form – 
Sleep -Related Impairment  (8a) 24-hour recall  and Short 
Form – Sleep Disturbance ( 8b) 24-hour recall  score at 
Weeks 2, 4, and 8. 
• PROMIS Short Form – Sleep -Related Impairment (8a) 7 -day 
recall  and Short Form – Sleep Disturbance (8b ) 7-day recall  
score at Week s 8, 12, 24, and 52. 
• Change from baseline in AD afflicted %BSA at every visit.  

Incyte Corporation   Page 33 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB  2019  
CONFIDENTIAL  Table 5: Objectives and Endpoints  (Continued)  
Objectives  Endpoints  
To evaluate  the participants ' Quality of Life and other patient -
reported outcomes . • Change from b aseline in POEM score at each visit.  
• Chan ge from b aseline in DLQI  score at Weeks 2, 4, 8, 1 2, 
24, and 52 and at unscheduled visits.  
• Mean PGIC score at Weeks 2, 4 , and 8. 
• Proportion of participants with each score on the PGIC at 
Weeks 2, 4 , and 8. 
• Proportion of participants with a score of  either  1 or 2 on the 
PGIC at Weeks 2, 4, and 8.  
• Change fr om b aseline in EQ -5D-5L score during the VC 
period.  
• Change from b aseline in WPAI -SHP v2.0 at Weeks  2, 4, 8, 
12, 24, 36, and 52.  
To evaluate the pharmacokinetics of ruxolitinib cream in 
plasma.  Trough plasma concent rations of ruxolitinib at all study visit s. 

Incyte Corporation   Page 34 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB  2019  
CONFIDENTIAL  4. STUDY DESIGN 
4.1. Overall Design  
This is a randomized, VC  study in adolescent and adult (≥ 12 years old) participants with AD 
eligible for topi[INVESTIGATOR_8588].  Approximately 600 participants will be randomized 2:2:1 to 
ruxolitinib  0.75% cream BID , ruxolitinib 1.5% cream BID , or vehicle cream .  In addition, 
approximately 20% of the overall study population will consist of adolescents.  Participants with baseline IGA score of 2 will constitute up to approximately 25% of the overall study population.  Participants with AD involvement of 3% to 20% BSA and IGA score of [ADDRESS_675424] met all study inclusion criteria and none of the exclusion crit eria, 
study drug assignment will be obtained.  Key entry criteria for participants to be eligible for the 
8-week VC treatment period is a diagnosis of AD (as defined by [CONTACT_190064]) 
with a duration of disease for a t least 2 years , IGA sc ore of 2 to 3, and a % BSA involvement of 
3% to 20% (excluding scalp) at screening  and b aseline.  
Participants who develop additional areas of AD may treat these additional areas with approval 
by [CONTACT_393602] 20%, and there are no safety 
concerns regarding the additional application of study drug.  Approval to treat additional areas 
may occur via telephone during the VC period, although the investigator, at his/her discretion , 
may ask the participant to return for an unscheduled visit.  Through Week 8, participants should 
continue to treat areas iden tified for treatment at b aseline even if the areas begin  to improve. 
At Week 8, the study's primary endpoint, participants will be assessed for efficacy with a percentage of participants achieving a treatment response in IGA  score.  Participants will also be 
assessed for safety and tolerability by [CONTACT_190060], duration, and severity of AEs;  
performing physical examinations; and collecting vital signs and clinical/laboratory assessments at various time points during the study. 
Participants who complete Week [ADDRESS_675425] to %BSA , there is no r equired lower limit; participants may have BSA  in the range of 0%  
to 20%. 
In the LTS period, participants will have study visits every 4 weeks  until the end of the study 
(52 weeks total).  At those visits, AD lesions will be evaluated by [CONTACT_501022] (IGA ≥ 1) or can otherwise (re)enter the 
observation/no treatment cycle (IGA = 0).  

Incyte Corporation   Page 35 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB  2019  
CONFIDENTIAL  During the LTS period (ie, after the Week 8 visit), participants will self -evaluate recurrence of 
AD and will treat areas of the skin with active AD changes  (not to exceed 20% BSA).  If lesions 
clear between study visits, participants will stop treatment applications [ADDRESS_675426] sign of recurrence.  In the 
event that  new lesions are outside of the usual location and/or are more wide spread than at 
baseline, the participant is required to contact [CONTACT_393604].  Approval to treat additional areas may occur via telephone during the LTS period, alth ough the investigator, at his/her 
discretion, may ask the participant to return for an unscheduled visit.  This is  a close reflection of 
the clinical practice of managing  AD in the outpatient setting.  
4.2. Overall Study Duration  
Participants will be on study fo r a duration of up to 60 weeks (28 days screening, 8 weeks of 
treatment in the VC  period, 44 weeks of treatment in the LTS  period, and a 30 (+  7)-day safety 
follow-up; see Figure  1). 
The study will begin when the fi rst participant (or parent or guardian) signs the ICF  (and if 
needed , an assent form) .  The end of the study is defined as the date of the last visit of the last 
participant in the study  or discontinued study drug and have completed applicable follow-up 
assessments . 
A participant is considered to have completed the study if he/she has completed all study visits, 
including the follow- up visit.  
The investigator will be expected to monitor for and report any SAEs and pregnancies, as 
detailed in Section  9.  The remaining participants are considered to be on study until a 
discontinuation criterion is met and written notification is provided to the sponsor. 
4.3. Study Termination  
The investigator retains the right to terminate study participation at any time, according to the terms specified in the study contract.  The investigator is to notify the IRB/IEC in writing of the study's completion or early termination, send a copy of the notification to the sponsor or 
sponsor' s designee, and retain 1  copy for the site study regulatory file.  
The sponsor may terminate the study electively, or if required by [CONTACT_352931].  In the event 
of significant safety findings, the study will be terminated.  If the study is terminated 
premat urely, the sponsor will notify the investigators, the IRBs and IECs, and regulatory bodies 
of the decision and reason for termination of the study. 

Incyte Corporation   Page 36 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB  2019  
CONFIDENTIAL  5. STUDY POPULATION  
Deviations from eligibility criteria are not allowed because they can potentially jeopardiz e the 
scientific integrity of the study, regulatory acceptability, and/or participant  safety .  Therefore, 
adherence to the criteria as specified in the Protocol is essential .  Prospective approval of 
Protocol deviations to recruitment and enrollment criteria, also known as Protocol waivers or 
exemptions, are not permitted. 
5.1. Inclusion Criteria 
Participants are eligible to be included in the study only if all of the following criteria apply:  
1. Adolescents  aged ≥ 12 to 17 years, inclusive, and men and women aged ≥ 18 years . 
2. Participants diagnosed with AD as defined by [CONTACT_85811] ( 1980 ) criteria.  
3. AD duration of at least 2 years . 
4. Participants with an IGA score : 
a. VC period:  2 to 3 at s creening  and baseline  
b. LTS period:  0 to 4 at Week 8  
5. Participants  with % BSA (excluding scalp) of AD involvement: 
a. VC period:  3% to 20% at s creening  and b aseline  
b. LTS period:  0% to 20% at Week [ADDRESS_675427] 1  "target lesion " that measures approximately [ADDRESS_675428] be representative of the participant' s disease 
state and not be located on the hands, feet, or genitalia. 
8. Willingness to avoid pregnancy or fathering of children based on the criteria below: 
a. Woman of nonchildbearing potential (surgically sterile with a hysterectomy and/or 
bilateral oophorectomy OR postmenopausal, defined by [CONTACT_190068] ≥ 12 months of amenorrhea before screening confirmed by [CONTACT_319852]) 
and at least 50 years of age ) are exempt from pregnancy testing. 
b. Woman of childbearing potential who has a negative serum pregnancy test at screening and a negative urine pregnancy test before the first dose on Day 1 and who agrees to take appropriate precautions to avoid pregnancy (with at least 99% certainty) from screening through safety follow -up (30 [ + 7] days after EOT ) 
(see Appe ndix A ).  Permitted methods that are at least 99% effective in preventing 
pregnancy should be communicated to the participant and their understanding confirmed. 
c. Adolescents who are prepubescent. 

Incyte Corporation   Page 37 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB  2019  
CONFIDENTIAL  d. Man who agrees to take appropriate precautions to avoid fathering children (with at 
least 99% certainty) or from sperm donation from screening through [ADDRESS_675429] 99% effective in preventing pregnancy (see Appendix A ) should be communicated to the participant  
and their understanding confirmed. 
9. Ability to comprehend and willingness to sign an ICF or written informed consent of the 
parent(s) or legal guardian and  written assent from the participant when  possible. 
Note:   Adolescent  participants who become legal adults during the study will be asked for 
their signed consent to continue the study, and in the event of lack thereof, will be 
discontinued from further participation.  
5.2. Exclusion Criteria  
Participa nts are excluded from the study if any of the following criteria apply: 
1. Participants who have an unstable course of AD (spontaneously improving or rapi[INVESTIGATOR_166462]) as determined by [CONTACT_99824] 4 weeks prior to baseline.  
2. Participants with concurrent conditions and history of other diseases: 
a. Immunocompromised (eg, lymphoma, acquired immunodeficiency syndrome, 
Wiskott-Aldrich s yndrome).  
b. Chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antip rotozoals, or antifungals within 2 weeks before b aseline. 
c. Active acute bacterial, fungal, or viral skin infection (eg, herpes simplex, herpes zoster, chicken pox) within 1 week before b aseline . 
d. Any other concomitant skin disorder (eg, generalized erythrode rma such as Netherton  
syndrome), pi[INVESTIGATOR_371], or extensive scarring that, in the opi[INVESTIGATOR_871], may interfere with the evaluation of AD lesions or compromise participant  safety.  
e. Presence of AD lesions only on the hands or feet without prior history of involvement of other classical areas of involvement such as the face or the folds.  
f. Other types of eczema.  
3. Any serious illness or medical, physical, or psychiatric condition(s) that, in the 
investigator 's opi[INVESTIGATOR_1649], would interfere with full partic ipation in the study, including 
administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of  study data.  For example: 
a. Clinically significant or uncontrolled cardiac disease, including unstable angina, acute 
myocardial infarction within 6 months from Day 1 of study drug administration, [LOCATION_001] Heart Association Class III or IV congestive heart failure, and arrhythmia requiring therapy or uncontrolled hypertension (blood pressure > 150/90 mmHg) unless approved by [CONTACT_131989]/sponsor. 
b. Participants  with a history of maligna ncy in the 5 years preceding enrollment into this 
study, except  for adequately treated, nonmetastatic malignancies.  
c. Low hemoglobin (<  10 g/dL) . 

Incyte Corporation   Page 38 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB  2019  
CONFIDENTIAL  d. Severe r enal disease on dialysis (serum creatinine > 2 mg/dL).  
e. Current and/or liver disease history , including known hepatitis B or C, with hepatic or 
biliary abnormalities . 
4. Participants using any of the following treatments within the indicated washout period 
before b aseline: 
a. 5 half- lives or 12 weeks, whichever  is longer – biologic agents (eg, dupi[INVESTIGATOR_12458]).  
b. 4 weeks – systemic corticosteroids or adrenocorticotropic hormone analogs, 
cyclosporin, methotrexate, azathioprine, or other systemic immunosuppressive or immuno modulating agents (eg, mycophenolate or tacrolimus). 
c. 2 weeks – immunizations and sedating antihistamines , unless on long- term stable 
regimen (nonsedating antihistamines are permitted).  
d. 1 week – use of othe r topi[INVESTIGATOR_117928] (other than bland emoll ients) , such as 
corticosteroids, calcineurin inhibitors, coal tar (shampoo), antibiotics, antibacterial cleansing body wash/soap.  Diluted sodium hypochlorite " bleach " baths are allowed 
as long as they do not exceed [ADDRESS_675430] previously received JAK inhibitors, systemic or topi[INVESTIGATOR_2855]. 
6. Ultraviolet light therapy or prolonged exposure to natural or artificial sources of UV 
radiation (eg, sunlight or tanning booth) within 2 weeks prior to b aseline and/or intention 
to have such exposure during the study, which is thought by [CONTACT_520711]' s AD.  
7. Positive serology test results at screening for HIV antibody.  
8. Liver function tests:  AST or ALT  ≥ 2 × ULN ; alkaline  phosphatase and/or bilirubin  
> 1.5 × ULN (isolated bilirubin > 1.5 × ULN is acceptable if bilirubin is fractionated and direct bilirubin < 35%). 
9. Pregnant or lactating participants , or those considering pregnancy. 
10. History of alcoholism or drug addiction within 1 year before screening or current alcohol or drug use that, in the opi[INVESTIGATOR_871], will interfere with the participant 's 
ability to comply with the administration schedule and study assessments.  
11. Current treatment or tre atment within 30  days or 5 half-lives (whichever is longer) before 
baseline with another investigational medication or current enrollment in another 
investigational drug protocol. 
12. Participants who, in the opi[INVESTIGATOR_871], are unable or unl ikely  to comply with 
the administration schedule and study evaluations. 
13. Participants who are committed to a mental health institution by [CONTACT_393606].  
14. Employees of the sponsor or investigator or are otherwise dependents of them. 

Incyte Corporation   Page 39 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB  2019  
CONFIDENTIAL  5.3. Lifestyle Considerations  
Prolonged exposure to natural or artificial sources of ultraviolet radiation (including sun lamps, 
tanning booths , etc)  is prohibited from [ADDRESS_675431] 1 hour before 
bedtime .  The strengths for ruxolitinib cream are 0.75% and 1.5% in a cream formulation and  the 
matching vehicle cream formulation that  does not contain active drug. 
On the first  clinic visit day  and subsequent study visits, the participant or guardian applies a thin 
film of study drug  by [CONTACT_520712] .  The  amount of study drug used per application will be determined by 
[CONTACT_17832] a tube before and after the participant or guardian applies study drug to the affected 
areas . 
On subsequent study visit days , participants should not apply the study drug at home (morning 
appli cation) .  The first application of the day will be done at the clinic. 
In general, the amount of study drug used per day (BID application) should not exceed 
one-fourth (1/4) of the [ADDRESS_675432] approximately 20% BSA of lesions on their body. 
At the baseline visit
, an estimate of the %BSA to be treated will be used by [CONTACT_520713].  All areas identified at baseline 
should continue to be treated through the end of the VC  period (Week 8 ) unless the participant  
meets criteria for stoppi[INVESTIGATOR_11743].  If there are new areas to be treated, including expansion 
of existing areas or develo pment of new areas, after consultation with the investigator, study 
drug should be applied to these areas in addition to the areas treated at baseline (up to 20% 
BSA), and the percentage of BSA to be treated will be recalculated and increased.  This new 
estimate will be entered into the IRT system to calculate the number of tubes of study drug to be 
dispensed. 
During the LTS period starting at the Week [ADDRESS_675433] study visits every 
4 weeks until the end of the study (52 weeks total).  A t those visits, AD lesions will be evaluated 
by [CONTACT_520714] 
(IGA  ≥ 1) or can ot herwise (re)enter the observation/no treatment cycle (I GA = 0).  At Week 8, a 
participant will receive a prespecified number of tubes with study medication corresponding to a lower %BSA affected (up to 5%) or higher number of tubes corresponding to their affected 
%BSA (> 5%).  This new estimate will be entered into the IRT system to calculate the numbe r of 
tubes of study drug to be dispensed.   
In-between study visits, the participant will self -evaluate recurrence of AD and will treat all 
areas identified with active AD changes (not to exceed 20% BSA).  If lesions clear between 
study visits, participants will stop treatment applications [ADDRESS_675434] sign of recurrence.  In the event that 
new lesions are outside of the usual location and/or are more widespread than at bas eline, the 
participant is required to contact [CONTACT_393604].  Approval to treat additional areas may 

Incyte Corporation   Page 41 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB  2019  
CONFIDENTIAL  occur via telephone during the LTS period, although the investigator, at his/her discretion, may 
ask the participant to return for an unscheduled visit.  
Application instructions will be provided by [CONTACT_233528] , and the participant will record 
their daily applications via a diary card given to the participants  during each study visit.  Refer to  
the Study Pharmacy Manual for participant instru ctions for handling study of drug.   Table 6 
presents the study treatment information.  
Table 6: Study Treatment Information  
 Study Treatment 1  Study Treatment 2  Study Treatment 3 
Study treatment name:  [CONTACT_393632]:  Cream  Cream  Cream  
Unit dose strength(s)/dosage 
level(s):  0.75%  1.5%  Not applicable  
Administration instructions : Topi[INVESTIGATOR_2855]: 
BID (mo rning and 
evening applications).  
A thin film is applied to 
the affected areas in the 
morning and in the evening at least 1 hour before bedtime . Topi[INVESTIGATOR_2855]: 
BID (morning and 
evening applications) . 
A thin film is applied to the affected areas in the morning and in the evening at least 1 hour before bedtime.  Topi[INVESTIGATOR_2855]: 
VC period:  BID (morning 
and evening application) . 
A thin film is applied to 
the affected areas in the 
morning and in the evening at least 1 hour before bedtime . 
LTS period:  Not 
applicable   
Packaging and labeling:  Study treatment 1  will be 
provided in 60 g tube.  
Each tube will be labeled as required per country 
requirement.  Study treatment 2  will be 
provided in 60 g tube.  
Each tube will be labeled 
as required per country 
requirement.  Vehicle  will be provided 
in 60 g tube.  
Each tube will be label ed 
as required per country requirement.  
Storage:  15°C -30°C (59°F -86°F) 15°C -30°C (59°F -86°F)  15°C -30°C (59°F -86°F)  
Status of treatment in 
participating countries:  Investigational  Investigational  Not applicable  
6.2. Preparation , Handling , and Accountabilit y 
The investigator or designee must confirm appropriate temperature conditions (both ruxolitinib 
cream  and vehicle cream are to be stored between 15°C and 30°C [59°F-86°F ]) have been 
maintained during transit for all study treatment s received and any discrepancies are reported and 
resolved before use of the study treatmen t. 
Only participants enrolled in the study may receive study treatment , and only authorized site 
staff may supply study treatmen t.  Immediately after application of ruxolitinib cream, 
partici pants are to wash hands thoroughly with soap and warm water.  Refer to the Study 
Pharmacy Manual for participant instructions for handling of study drug. 
All study treatment must be stored in a secure, environmentally controlled, and monitored 
(manual or a utomated) area in accordance with the labeled storage conditions with access limited 
to the investigator and authorized site staff .  Participants should store study treatment at ambient 
temperature conditions. 

Incyte Corporation   Page 42 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB  2019  
CONFIDENTIAL  The investigator (or designee)  is responsible for study treatment accountability, reconciliation, 
and record maintenance (ie, receipt, reconciliation, and final disposition records).  Inventory and 
accountability records must be maintained and readily available for inspection by [CONTACT_319853] .  The 
investigator or designee must maintain records that document: 
• Delivery of study drug(s)  to the study site.  
• Inventory of study drug (s) at the site.  
• Participant use of the stud y drug (s) including tube counts from each supply 
dispensed. 
• Return of study drug (s) to the investigator or designee by [CONTACT_4317].  
The investigational product must be used only in accordance with the Protocol.  The investigator 
will also maintain record s adequately documenting that the participants were provided the 
specified study drug.  These records should include dates, quantities, and any available batch or 
serial numbers or unique code numbers assigned to the investigational product and study 
participants.  
Completed accountability records will be archived by [CONTACT_779] .  The investigator or designee will 
be expected to collect and retain all used, unused, and partially used containers of study drug until verified by [CONTACT_11200] (unless otherwise agreed to by [CONTACT_456]).  At the 
conclusion of the study, the investigator or designee will oversee shipment of any remaining study drug back to the sponsor or its designee for destruction according to institutional standard 
operating procedures.  If local procedures mandate on -site destruction of investigational supply, 
the site should (where local procedures allow) maintain the investigational supply until the study 
monitor inspects the accountability records in order to evaluate compliance and accurac y of 
accountability by [CONTACT_3878] .  At sites where the study drug is destroyed before 
monitor inspection, the monitors rely on documentation of destruction per the site SOP. 
Further guidance and information for the final disposition of unused s tudy treatments are 
provided in the study materials provided to sites. 
6.3. Measures to Minimize Bias:  Randomization and Blinding  
All participants will be centrally assigned to study treatment using an IRT system .  The system 
will assign in a 2:2:1 ratio , stra tified by [CONTACT_393611] (2,  3) and region (North America or other),  
the participant  study number, track participant  visits, randomize according to the defined 
parameters, maintain the blinding, and manage study drug inventory.  Full details will be 
provided in the IRT Manual.   Study treatment will be dispensed at the study visits summarized in 
the SoAs (see Table 3 and Table 4). 
6.4. Study Treatment Compliance  
Compliance with all study- related treatments must be emphasized to the participant by [CONTACT_89184], and appropriate steps should be taken to optimize compliance during the study.  Compliance with ruxolitinib
 cream will be evaluated by [CONTACT_4317] ' adherence to the application 
regimen and drug accountability documented by [CONTACT_520715]/designee (tube counts). 

Incyte Corporation   Page 43 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB  2019  
CONFIDENTIAL  In general, the application compliance will be determined by [CONTACT_352937], which should be within 80% to 120% of the prescribed 
number of applications during the VC period, unless otherwise discussed/approved by [CONTACT_103].  Participants will be instructed to bring all study drugs with them to the study visits in 
order for site personnel t o conduct tube counts to assess study drug accountability.  The drug 
accountability documentation will be used by [CONTACT_147097]. 
6.5. Modifications to Treatment Regimen  
Through Week 8, participants should continue to treat areas identified for treatment at baseline even if the area begins to improve.  Participants who develop new AD lesions during the course 
of the study may treat these additional areas, with approval by [CONTACT_093], as long as the 
total treated BSA does not exceed 20% and there are no safety concerns.  Approval to treat additional areas may occur via telephone during the VC  period, although the investigator may 
request to have the participant come in to have an unscheduled visit, if needed. 
After Week 8, for participants enrolled in the LTS period, only areas with active disease should 
be treated.  Once the lesions are cleared, participants should continue to apply study drug for an 
additional [ADDRESS_675435] present bef ore discontinuing 
the treatment.   In the event that the new lesions are significantly more extensive than from the 
previous visit, the participant should call the study site to discuss with the investigator whether  
additional evaluation at the clinic is re quired. 
6.5.1. Criteria and Procedures for Application Interruptions of Study Drug  
Safety concerns should be discussed with the sponsor immediately upon occurrence or awareness 
to determine whether the participant should continue or discontinue study treatment. 
In some circumstances, it may be necessary to temporarily interrupt treatment with ruxolitinib 
cream.  Except in cases of emergency, it is recommended that any findings of concern (eg, AE) 
be confirmed and that the investigator consult with the sponsor medical monitor (or other 
representative of the sponsor) before interrupting study drug.  Additionally, the investigator must 
obtain approval from the sponsor before restarting study drug.  Participants who experience a recurrence of the initial AEs upon restarting the study drug may need the study drug to be 
permanently discontinued. 
Instructions for application interruptions for ruxolitinib cream are outlined in Table 7.  Individual 
decisions regarding interruptions should be made using clinical judgment in consultation with the 
medical monitor (whenever possible), taking into account relatedness of the AE to the study 
treatment and the participant 's underlying condition. 

Incyte Corporation   Page 44 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB  2019  
CONFIDENTIAL  Table 7: Guidelines for Interruption and Restarting of Study Drug  
ADVERSE EVENTa ACTION TAKEN  
Chemistry  
ALT (> 3 × ULN) or AST (> 3 × ULN)  • Laboratory abnormalities should be confirmed with repeat 
testing within 48 hours whenever possible and immediate 
delivery of th e laboratory results requested.  
• Study drug applications must be interrupted .   
• At the discretion of the investigator, after consultation 
with the sponsor, study drug application may be restored 
once these have resolved.  
Hematology  
Grade 2 decrease in ANC (< 1.5 × 109/L) • Laboratory abnormalities should be confirmed with 
repeat testing within 48 hours whenever possible and immediate delivery of the laboratory results requested. 
• Study drug applications must be interrupted.  At the discretion of the investigator, after consultation with the sponsor, study drug application may be restored once these have resolved.  
Any other Grade 3 or higher laboratory abnormality 
(eg, hemoglobin with the exception of asymptomatic elevations in trigly ceride, cholesterol, or amylase)  • Laboratory abnormalities should be confirmed with repeat testing within 48 hours whenever possible and immediate delivery of the laboratory results requested.  
• Study drug applications must be interrupted.   At the 
discretion of the investigator, after consultation with the sponsor, study drug application may be restored once these have resolved.  
Any Grade [ADDRESS_675436] or ALT 
(> 5 × ULN)  • Laboratory abnormalities should be confirmed with repeat testing within 48 hours whenever possible and 
immediate delivery of the laboratory results requested.  
• Discontinue study drug  if lab abnormalities are 
confirmed . 
a In the opi[INVESTIGATOR_393581].  
6.5.2. Criteria for Permanent Discontinuation of Study Drug  Due to an Adverse Event  
The occurrence of unacceptable severity of an AE  not caused by [CONTACT_520716] w ill require that the study drug be 
permanently discontinued.  Unacceptable severity is defined as follows: 
• Occurrence of an AE that is related to treatment with the study drug that, in the 
judgment of the investigator or the sponsor's medical monitor, compromised the 
participant 's ability to continue study -specific procedures, or is considered to not be in 
the participant 's best interest.  
• Participant presents with a worsening of AD that requires treatment with a prohibited 
concomitant medication . 
• Persisten t AE requiring a  delay of therapy for more than 2 weeks without resolution 
of the AE. 
See Section  7 for discontinuation procedures. 

Incyte Corporation   Page 45 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB  2019  
CONFIDENTIAL  6.6. Concomitant Medications  and Procedures  
All concomitant medications and treatments (including over-the-counter or prescription 
medicines, vitamins, vaccines, and/or herbal supplements) must be recorded in the eCRF.  Any 
prior medication received up to [ADDRESS_675437] dose of study treatment should 
be recorded for SAEs as defined in Section  9.3.  Concomitant treatments/procedures that are 
required to manage a participant 's medical condition during the study will also be recorded in the 
eCRF.  The medical monitor should be contact[CONTACT_31182]. 
6.6.1. Permitted Medications and Procedures  
The following are permitted during the study: 
• Participants may use bland emollients such as Eucerin
® cream.  
Note:   Emollients should not be used within the following periods from the 
application of study drug:  4 hours before and 2 hours after application. 
• Bathing during the study should be limited to once daily for no longer than 
15 minutes.  During baths, tepid (not hot) water and mild cleansing agents (eg, Basis® 
bar or Dove®) should be used.  (See Section  5.3 for swimming guidance.)  Showers 
should be limited in time with  warm water and mild cleansing agents used.  
• If sunscreen is needed, a mineral -based sunscreen (such as zinc oxide– or titanium 
oxide–based) with SPF of at least [ADDRESS_675438] 2  hours after study drug application. 
• Participants may use nonsedating, over-the- counter antihistamines.  
6.6.2. Restricted Medications and Procedures  
The following are permitted during the study under specified conditions: 
• Use of any over -the-counter, nonprescription preparations (including vitamins, 
minerals, and phytotherapeutic, herbal, or plant derived preparations) within 7 days 
before the baseline visit through the follow-up visit, unless deemed acceptable by [CONTACT_093].  
• Use of any prescription medication (including immunizations, phytotherapeutic, 
herbal, or plant-derived preparations) within 7 days before the baseline visit through 
the follow-up visit, unless deemed acceptable by [CONTACT_093]. 
• Bleach baths are allowed as long as they do not exceed 2 baths per week and their 
frequency remains the same throughout the study. 
• Participants should not take baths or showers within 2 hours after study drug  
application . 
• Topi[INVESTIGATOR_900] -infectives or other topi[INVESTIGATOR_520704] 4 hours before and 2 hours after application of study drug. 

Incyte Corporation   Page 46 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB  2019  
CONFIDENTIAL  6.6.3. Prohibited Medications and Proc edures  
The following are not permitted during the study:   
• Any investigational medication other than the study drug. 
• Topi[INVESTIGATOR_11930], tacrolimus, pi[INVESTIGATOR_031], and PDE4-inhibitors (Eucrisa®). 
• Other topi[INVESTIGATOR_393583] (except bland emollients as noted in Section 6.6.1).  
• Treatment known to affect the course of AD. 
• Systemic corticosteroids, methotrexate, cyclosporine A, azathioprine and biological 
therapi[INVESTIGATOR_014], or other immunosuppressant agents. 
• Allergen immun otherapy  
• Phototherapy or tanning beds. 
• Live or live -attenuated vaccination.  
6.7. Treatment After the End of the Study  
 There will be no treatment provided after the end of the study. 

Incyte Corporation   Page 47 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB  2019  
CONFIDENTIAL  7. DISCONTINUATION OF STUDY TREATMENT AND 
PARTICIPANT DISCONTI NUATION/WITHDRAWAL  
7.1. Discontinuation of Study Treatment  
7.1.1. Reasons for Discontinuation 
Participants must  be discontinued from study treatment for the following reasons: 
• Due to lack of efficacy response during the LTS (defined as no change/improvement 
in either % BSA or IGA when tr eated continuously for 8 weeks).   
• The participant becomes pregnant. 
• Consent is withdrawn.   Note:   Consent withdrawn means that the participant has explicitly indicated that they 
do not want to be followed any longer; in this case no further data, except data in 
public domain, may be solicited from or collected on the participant.  Participants may choose to discontinue study treatment and remain in the study to be followed for 
progression and survival. 
• Further participation would be injurious to the parti cipant 's health or well-being, in 
the investigator 's medical judgment.  
• Any adverse event of unacceptable severity as noted in Section  6.5.2. 
• The study is terminated by [CONTACT_456]. 
• The study is terminated by [CONTACT_19407], IRB, or IEC. 
A participant  may be discontinued from study treatment as follows:  
• If, at 2 consecutive study visits, a participant' s drug usage exceeds one 60 g tube pe r 
4 days .  The medical monitor  should be consulted for instruction on handling the 
participant.  
• If, during the course of the study, a participant is found not to have met eligibility 
criteria, the medical monitor, in collaboration with the investigator, will determine 
whether the participant should be withdrawn from stud y treatment.  
• If a participant is noncompliant with study procedures or study drug/treatment 
administration in the investigator 's opi[INVESTIGATOR_1649], the medical monitor  should be consulted 
for instruction on handling the participant. 
7.1.2. Discontinuation Procedures  
In the event that the decision is made to permanently discontinue the study treatment, the EOT 
visit should be conducted.  Reasonable efforts should be made to have the participant return for a 
follow-up visit.  The last date of the last dose of study drug(s)/tr eatment and the reason for 
discontinuation of study treatment will be recorded in the eCRF. 

Incyte Corporation   Page 48 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB  2019  
CONFIDENTIAL  If a participant is discontinued from study treatment:  
• The study monitor or sponsor must be notified. 
• The reason(s) for withdrawal must be documented in the participant' s medical record 
and the primary reason for withdrawal must be included in the eCRF. 
• The EOT visit should be performed. 
• The date of the EOT visit should be recorded in the eCRF. 
• Participants must be followed for safety until the time of the follow -up visit or until 
study drug/treatment–related AEs resolve, return to baseline, or are deemed 
irreversible, whichever is longest.  
If the participant discontinues study treatment and actively withdraws consent for collection of 
follow-up data (safety follow-up), then no additional data collection should occur; however, 
participants will have the option of withdrawing consent for study treatment but continuing in the follow-up period of the study for safety assessments.   
7.2. Participant Withdrawal From the Study  
A participant may withdraw from the study at any time at his/her own request, or may be withdrawn at any time at the discretion of the investigator for safety, behavioral, compliance, or administrative reasons.  
If the participant withdraws consent for disclosure of future information, the sponsor may retain and continue to use any data collected before such a withdrawal of consent.   If a participant 
withdraws from the study, he/she may request destruction of any samples taken and not tested, 
and the investigator must document this in the site study records. 
Data to be collected at the time of study discontinuation and follow -up and for any further 
evaluations should conform to the requirements of the ET/EOT visit (see Ta ble 3 and Table 4).  
7.3. Lost to Follow -Up 
A participant  will be considered lost to follow -up if he/she repeatedly fails to return for 
scheduled visits and is unable to be contact[CONTACT_9298].  The following actions must be 
taken if a participant fails to return to the clinic for a required study visit: 
• The site must attempt to contact [CONTACT_520717]/or 
should continue in the study. 
• Before a participant is deemed lost to follow -up, the investigator or designee must 
make reasonable effort to regain contact [CONTACT_126719] (where possible, 
3 telephone calls and, if unsuccessful , a certified letter to the participant 's last known 
mailing address or local equivalent methods).  These contact [CONTACT_13140]' s medical record.  
• Should the participant continue to be unreachable, he/she will be considered to have withdrawn from the study. 

Incyte Corporation   Page 49 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB  2019  
CONFIDENTIAL  8. STUDY ASSESSMENTS AND PROCEDURES  
8.1. Administrative and General Procedures  
8.1.1. Informed Consent Form Process  
• The investigator or his/her representative will explain the nature of the study to the 
participant or his/her legally authorized representative and answer all questions 
regarding the study. 
− Informed consent /assent  must be obtained from the participant and/or parent or 
guardian before any study- related procedu res are conducted, unless otherwise 
specified by [CONTACT_89191]. 
Note:   Adolescent  participants who become legal adults during the study will be 
asked for their signed consent to continue the study, and in the event of lack 
thereof, will be discontinued from further participation. 
− Informed consent/a ssent  must be obtained using the IRB/IEC-approved version in 
a language that is native and understandable to the participant.  A template will be provided by [CONTACT_3552].  The sponsor or its designe e must review 
and acknowledge the site -specific changes to the ICF /assent  template.  The 
ICF/assent  must include a statement that the sponsor or its designee and 
regulatory authorities have direct access to participant records.  
− The ICF /assent  must contain all required elements and describe the nature, scope, 
and possible consequences of the study in a form understandable to the study participant.  
• Participants must be informed that their participation is voluntary.  Participants or 
their legally authorized r epresentative will be required to sign a statement of informed 
consent /assent  that meets the applicable requirements and regulations for the 
countries in which the study is being conducted as well as the IRB/IEC or study center.  
• The participant must be informed that his/her personal study- related data will be used 
by [CONTACT_89192].  The level of disclosure 
must also be explained to the participant. 
• The participant must be informed that his/her medical records may be examined by 
[CONTACT_340764], by [CONTACT_6667]/IEC members, and by [CONTACT_9326].  
• The medical record must include a statement that written informed cons ent/assent  
was obtained before the participant was enrolled in the study and the date the written consent was obtained.  The authorized person obtaining the informed consent must 
also sign the ICF/a ssent . 

Incyte Corporation   Page 50 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB  2019  
CONFIDENTIAL  • Participants must provide consent to the most current version of the ICF(s) /assent(s)  
during their participation in the study.  
• A copy of the signed  ICF(s) /assent(s)  must be provided to the participant or the 
participant 's legally authorized representative.  
• Participants who are rescreened are required to si gn a new ICF /assent  and must be 
assigned a new participant number. 
8.1.2. Screening Procedures  
Screening is the interval between signing the ICF /assent  and the day the participant is enrolled in 
the study (Day 1).  Informed consent (or assent) must be obtained be fore performing any 
study- specific procedures.   Screening may not exceed 28  days.  Assessments that are required to 
demonstrate eligibility may be performed over the course of 1 or more days during the screening 
process.  
Procedures conducted as part of the  participant' s routine clinical management by [CONTACT_393614] (eg, blood count) and obtained before signing of informed consent /assent  may be used 
for screening or baseline purposes provided the procedure meets the Protocol- defined criteria and 
has been performed in the timeframe of the study (ie, within 28 days of Day 1).  For participants 
who are enrolled in the study, information associated with eligibility requirements must be 
entered into the appropriate eCRF pages. 
Results from the s creening  visit evaluations will be reviewed to confirm eligibility before 
enrollment or the administration of study drug.  Tests with results that fail eligibility 
requirements may be repeated once during screening if the investigator believes the results to be in error.  For screening assessments that are repeated, the most recent available result before 
randomization/treatment assignment will be used to determine eligibility.  
See Section  5.[ADDRESS_675439] the IRT system to obtain the participant ID number during screening.  Upon determining that the participant is 
eligible for study entry, the IRT  system  will be contact[CONTACT_352940].  Additionally, the IRT sy stem  will be contact[CONTACT_520718].  Additional details are 
provided in the IRT M anual.  

Incyte Corporation   Page 51 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB  2019  
CONFIDENTIAL  8.1.4. Distribution of Study Reminder Cards and Diaries  
Starting at the Day 1 visit and each visit thereafter, a study drug –specific diary  will be given to 
each participant  in order to record use of the study drug.  The completed diary will be collected 
during each of  the participant 's visit s.   
Qualified clinical site staff will review  the participant s' entries for compliance.  Participant s who 
are noncompliant with their study drug schedule (defined as < 80% or > 120% of the expected 
number of applications between study visits ) will have their administration instructions 
reinforced by [CONTACT_1720] a qualified designee.  Participant s will be considered compliant 
with the treatment regimen if they apply at least 80% but no more than 120% of the expected 
applications during participation in th e treatment period of the study. 
Partici pants will be provided with a reminder card starting on Day [ADDRESS_675440] will indicate the date/time of the next visit and will also remind the participant that they should have their 1st morning application at the clinic unde r site supervision after their 
blood draws for PK and safety evaluations have been completed.  
8.1.5. Demography and Medical History 
[IP_ADDRESS]. Demographics and General Medical History  
Demographic data and general medical history will be collected at s creening  by [CONTACT_520719]/age , race, ethnicity, medical and surgical 
history, and current illnesses.  Medical history will include relevant medical  or surgical treatment 
within the last 2 years that are considered to be cli nically significant by [CONTACT_093].  
[IP_ADDRESS]. Medical and Treatment History  
Relevant  medical and treatment history f or the past  year will be collected at s creening  by [CONTACT_100924].  Details regarding the participant 's history of AD, including 
date of diagnosis, relevant disease characteristics, and prior treatments, including systemic treatments, radiation, and surgical procedures, will be recorded.  A medical history of other 
conditions related to AD will also be collected at this time . 

Incyte Corporation   Page 52 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB  2019  
CONFIDENTIAL  8.2. Efficacy Assessments  
8.2.1. Investigator' s Global Assessment  
The IGA  is an overall eczema severity rating on a 0 to 4 scale that will be assessed during site 
visits.  The grades for the IGA are shown in Table 8. 
Table 8: Investigator' s Global Assessment  
Grade  Severity  Status  
0 Clear  No erythema or induration/papulation, no oozing/crusting; there may be minor 
residual discoloration . 
[ADDRESS_675441] no induration/papulation, and 
no oozing/crusting. 
2 Mild  There may be faint pi[INVESTIGATOR_80169], with mild induration/papulation and no 
oozing/crusting. 
3 Moderate There may be pi[INVESTIGATOR_8745]-red erythema with moderate induration/papulation and there may be some oozing/crusting. 
4 Severe  There may be deep or bright red erythema with severe induration/papulation and with oozing/crusting. 
Source:  www.homeforeczema.org . 
The IGA-TS is defined as an  IGA score of 0 or 1  with ≥ 2 grade improvement from baseline.  
8.2.2. Eczema Area and Severity Index Score 
Atopic dermatitis will be assessed as outlined in the SoA ( see Table 3) using EASI  scoring 
system ( refer to Study Manual ), which is a validated disease measurement for clinical studies 
(Hanifin et al 2001) that  examines [ADDRESS_675442] 8 years of age.  Each of the 4 body regions is assessed separately for erythema (E), 
induration/papulation/edema (I), excoriations (Ex), and lichenification (l) for an average degree 
of severity of each sign in each region. 
The severity strata for the EASI are as follows:   0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 
7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 t o 72.0 = very severe 
(Leshem  et al 2015 ). 

Incyte Corporation   Page 54 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB  2019  
CONFIDENTIAL  8.2.5. Body Surfa ce Area  
Total % BSA  afflicted by [CONTACT_520720] ( see Table 3 and Table 4).  Body surface area assessment will be a pproximated to the 
nearest 0.1% using the Palmar Method as guides, the palm plus 5 digits, with fingers tucked 
together and thumb tucked to the side (handprint), as 1% BSA and the thumb as 0.1% BSA.  
8.2.6. Photography 
At selected sites, f or each visit with photog raphy ( baseline and  Weeks 2, 4, and 8), photography 
of the target lesion will be conducted via 2 views (close-up and regional body area).  Ad hoc photography of skin- related AEs is recommended  at selected sites to provide additional 
photographic documentation. 
8.2.7. Patient -Reported Outcomes  
Quality of l ife (QoL) will be assessed (see SoA s Table 3 and Table 4) using the following tools:  
DQLI, PGIC, POEM, EQ-5D- 5L, WPAI:SHP, Itch NR S, Skin Pain NRS, PROMIS Short 
Form  – Sleep -Related Impairment  (8a), and PROMIS Short Form – Sleep Disturbance ( 8b). 
In order to  avoid bias in the participants' responses to the questionnaires, a ll these assessments 
should be completed before any other eva luations or study procedures on the day of the study 
visit and prior to discussions with the investigator or study site staff . 
At the baseline visit, all patient-reported outcomes must be completed before the participant 's 
first study drug  application. 
Participants will be issued a paper questionnaire or hand- held device (eDiary) for daily 
assessments.  The participant will be instructed to complete the diary during specific timepoints 
needed for each assessment beginning on the day of screening through Week 8 or treatment discontinuation.  Detailed directions for the administration of an  eDiary will be provided in the 
Study Manual. 
Daily assessments will be performed by [CONTACT_520721] a diary  starting at  the screening visit and 
all visits  during the VC  period: 
• The participant will rat e (during the past 24 hours) the following: 
− Itch NRS – the worst level of itch will be recorded  in the evening. 
− Skin Pain NRS – the worst level of pain will be recorded in the evening . 
− PROMIS questionnaires: 
 Short Form  – Sleep -Related Impairment (8a) will be completed  in the 
evening . 
 Short Form – Sleep -Disturbance ( 8b) will be assessed in the morning. 
Note:   At Week 8 only (LTS baseline) for both PROMIS Short Form – 
Sleep -Related Impairment ( 8a) and Short Form – Sleep -Disturbance ( 8b), the 
“past 7 -day recall” assessment will also be completed using the tablet during the 
site visit.  

Incyte Corporation   Page 55 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB  2019  
CONFIDENTIAL  • Assessments to be completed  during all VC  site visits  include the following: 
− EQ-5D- 5L – starts at s creening  
− WPAI:SHP – starts at s creening  
− DLQI/CDLQI  – starts at Day 1  
− POEM  – starts at Day 1  
− PGIC  – starts at Week 2  
Assessments to be completed  at the site  during the LTS period ( see SoA Table 4 for timepoints ): 
• EQ-5D- 5L  
• WPAI:SHP  
• DLQI/CDLQI  
• POEM  
• PROMIS Short Form – Sleep -Related Impairment (8a) and Short Form – 
Sleep -Disturbance (8b): 
− As stated  above , this assessment will be completed during the LTS site visits  
(except for unscheduled visits) starting at Week 8 . 
Note :  The recall period for Weeks 8, 12, 24, and 52 during the LTS period changes 
to the “ past 7 days” from “the previous 24 hours” in the VC  period. 
Refer to the Study Manual for detailed instructions.  
[IP_ADDRESS]. Dermatology Life Quality Index 
The DLQI is a simple, 10-question validated questionnaire to measure how much the skin 
problem has affected the participant over the previous 7 days as outlined in the SoAs (see 
Table 3 and Table 4; Finlay a nd Khan 1994 ).  The participant, aged ≥ 16 years and over, will 
answer the questionnaire with either  (1) very much, (2) a lot , (3) a little , or (4) not at all.  
The questionnaire is analyzed under 6 headings as follows: 
• Symptoms and feelings (Questions 1 and 2) 
• Daily activities (Questions 3 and 4)  
• Leisure (Questions 5 and 6) 
• Work and school (Question 7) 
• Personal relations  (Questions 8 and 9) 
• Treatment (Question 10) 

Incyte Corporation   Page 56 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB  2019  
CONFIDENTIAL  CDLQI is the youth/children ’s version of the DLQI and will be completed by a dolescents aged 
≥ 12 years to < 16 years .  It is self -explanatory and can be simply given  to the participant who is 
asked to fill it in and who may ask the help of the parent or guardian.  The questionnaire is 
analyzed under 6 headings as follows: 
• Symptoms and feelings (Q uestions 1 and 2) 
• Leisure (Questions 4, 5, and 6) 
• School or holidays (Question 7) 
• Personal relationships (Questions 3 and 8) 
• Sleep (Question 9) 
• Treatment (Question 10) 
[IP_ADDRESS]. Patient Global Impression of Change 
The PGIC is a participants ' self-reporting measure t hat reflects their belief about the efficacy of 
treatment.  The PGIC is a 7 -point scale depi[INVESTIGATOR_155772] a participant 's rating of overall improvement 
and will be captured during site visits during the VC period ( Hurst and Bolton 2004). 
The participant will answer the following:  
"Since the start of the treatment you 've received in this study, your atopic dermatitis in areas 
treated with the study drug is:  (1) very much improved, (2) much improved, (3) minimally improved, (4) no change, (5) minimally worse, (6) much worse, and (7) very much worse." 
[IP_ADDRESS]. Patient -Oriented Eczema Measure  
The POEM  is a [ADDRESS_675443]  7 days obtained as 
outlined in the SoAs (see Table 3 and Table 4; Charman et al 20 04). 
[IP_ADDRESS]. EQ-5D-5L 
The EQ -5D is a validated, self -administered, generic utility questionnaire wherein participants 
(adolescents and adults) rate their current health state based on the following criteria (dimensions):  mobility, self -care, usual activities, pain/discomfort, and anxiety/depression. 
The 5L indicates that for each dimension, there are 5 levels, which are as follows:  no problems, slight problems, moderate problems, severe problems, and extreme problems.   
During all VC  period study visits  (starting at screening ) and at specific LTS visits (Weeks 12, 24, 
36, 52, and follow-up visit), t he participant will be asked to indicate his/her health state over the 
past [ADDRESS_675444] appropriate statement in each of the 5 
dimensions.  The digits for the 5  dimensions can be combined into a 5-digit number that 
describes the participant 's health state  (EuroQol Research Foundation 2017). 

Incyte Corporation   Page 57 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB  2019  
CONFIDENTIAL  [IP_ADDRESS]. Work Productivity and Activity Impairment Questionnaire:  Specific Health 
Problem Version 2.0 
The WPAI:SHP v2.0 questionnaire is a validated 6- item instrument, completed during all site 
visits starting at screening,  during the VC period, and at specific LTS visits (Weeks 12, 24, 36, 
52 and follow-up visit) that measures the effect of overall heal th and specific symptoms on 
productivity at work and regular activities outside of it during the past 7 days ( Reilly et al 1993 ). 
[IP_ADDRESS]. Itch Numerical Rating Scale 
The Itch NRS is a daily patient -reported measure ( 24-hour recall) of the worst  level of itch 
intensity.  Participants  will be asked to rate the itching severity because of their AD by [CONTACT_20683] 
a number from 0 (no itch ) to 10 (worst imaginable itch) that best describes their worst level of 
itching  in the past 24 hours as outlined in the SoA ( see Table 3).  
Participants will be issued a diary in  which to record itch  severity.  The participants will be 
instructed to complete the diary  each night beginning on the day of s creening  throu gh the last 
application of study drug in the VC  period.  Detailed directions for the administration of an  
eDiary will be provided in the Study Manual. 
[IP_ADDRESS]. Skin Pain Numerical Rating Scale 
The Skin Pain NRS is a daily patient -reported measure ( 24-hour recall) of the worst level of pain 
intensity  from 0 (no pain) to 10 (worst imaginable pain).  Participants will be asked , “Rate the 
pain severity from your atopic dermatitis skin changes by [CONTACT_20683] a number that best describes 
your worst level of pain in the past 24 hours,” as outlined in the SoA (see Table 3). 
Participants will be issu ed a diary in  which to record skin pain  severity  each evening , rating the 
worst pain in the past 24-hours.  The participants will be instructed to complete the diary each night beginning on the day of s creening  through the last application of study drug in the VC 
period.  Detailed directions for the administration of an  eDiary will be provided in the Study 
Manual.  
[IP_ADDRESS]. PROMIS Sleep Questionnaire s:  Short Form – Sleep -Related Impairment (8a) 
and Short Form – Sleep Disturbance (8b) 
PROMIS
® (Patient -Reported Outcomes Measurement Information System) is a set  of widely 
used and accepted patient -reported outcome measurements that have been developed with strong 
clinical outcome assessment development methods and are psychometrically supported.   
Note:   The selected PROMIS Short Form – S leep-Related Impairment (8a)  and Short Form – 
Sleep -Disturbance (8b) questionnaires have been modified to be completed wit h a diary on a 
daily  basis with a 24- hour recall :  Short Form – Sleep -Related Impairment (8a) is collected in the 
evening , and Short Form  – Sleep -Disturbance (8b) is collected in the morning during the VC 
period. 
Starting at Week 8 and d uring t he LTS period, these will be done with a 7-day recall period and  
be completed at the site during study visits .  For timing, see SoAs Table 3 and Table 4. 

Incyte Corporation   Page 58 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB  2019  
CONFIDENTIAL  These measures will be collected  from both adolescents and adults via a diary during the VC  
period and on a tablet at the site  during scheduled LTS period study visits .  Refer to  the Study 
Manual for detailed instructions. 
[IP_ADDRESS].1. PROMIS Short Form – Sleep -Related Impairment (8a) 
The PROMIS Shor t Form – Sleep -Related Impairment (8a) questionnaire, is to be completed in 
the evening during the VC  period.  This assessment  focuses on self-reported perceptions of 
alertness, sleepi[INVESTIGATOR_008], and tiredness during usual waking hours and the perceived functional 
impairments during wakefulness associated with sleep problems or impaired alertness (Buysse  et al 2010). 
The questionnaire has 8 simple questions with a 5-point scale with a range in score from 8 to 40, with higher scores indi cating greater severity of sleep -related impairment.  Each item asks the 
participant to rate the severity of the participant 's sleep impairment.  The recall  period will be  the 
past [ADDRESS_675445] 7  days  for the LTS period. 
[IP_ADDRESS].2. PROMIS S hort Form – Sleep Disturbance (8b) 
The PROMIS Short Form – Sleep Disturbance ( 8b) questionnaire is to  be completed in the 
morning during the VC  period .  This assessment is self -reported perceptions of sleep quality, 
sleep depth, and restoration associated with sleep .  Sleep disturbance does not focus on 
sympt oms of specific sleep disorders and does not provide subjective estimates of sleep 
quantities ( eg, total amount of sleep, time to fall asleep, amo unt of wakefulness during sleep; 
Buysse et al 2010 ).  The sleep disturbance short form is generic rather than disease- specific.  
The questionnaire is a lso 5-point scale with a range in score from 8 to 40, with higher scores 
indicating greater severity of sleep disturbance.  Each item asks the participant to rate the 
severity of the participant 's sleep disturbance.  The recall  period will be the past [ADDRESS_675446] 7 days for the LTS period. 
8.2.8. Health Economics  
Health economic data will be assessed through the WPAI and EQ-5D- 5L Questionnaire s (see 
Section  [IP_ADDRESS] and [IP_ADDRESS]). 
8.3. Safety Assessments  
Planned timepoints for all safety assessments are provided in the SoAs in Table 3 and Table 4. 
See Section  6.5 for guidelines regarding the management of relevant laboratory or other safety 
assessment abnormalities.  

Incyte Corporation   Page 59 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB  2019  
CONFIDENTIAL  8.3.1. Adverse Events  
Adverse events will be monitored from the time the participant signs the ICF /assent  until at least 
30 (+  7) days after the last dose of study drug.  Adverse events that begin or worsen after 
informed consent /assent  should be recorded on the Adverse Events Form in the eCRF regardless 
of the assumption of a causal relationship with the study drug.  Conditions that were already 
present at the time of informed consent /assent  should be recorded on the Medical History Form 
in the eCRF.  Adverse events (including laboratory abnormalities that constitute AEs) should be described using a diagnosis whenever possible rather than by [CONTACT_147108].  
Adverse events will be reported by [CONTACT_2299] (or, when appropriate, by a caregiver, surrogate, or the participant 's legally authorized representative).  The investigator and any 
qualified designees are responsible for detecting, documenting, and recording events that meet 
the definition of an AE or SAE and remain responsible for following-up on AEs that are serious, 
considered related to the study treatment/procedures, or that caused the participant to discontinue the study drug.  Care will be taken not to introduce bias when detecting AEs and/or SAEs.  
Open -ended and nonleading verbal questioning of the participant, such as "How are you 
feeling? " is the preferred method to inquire about AE occurrences.  Adverse events may also be 
detected when they are volunteered by [CONTACT_520722], o r through physical examinations, laboratory tests, or other assessments.  The definition, 
reporting, and recording requirements for AEs are described in Section  9. 
All SAEs will be recorded and reported to the sponsor or designee within 24 hours.  The investigator will submit any updated SAE data to the sponsor within 24 hours of it being 
available.  
After the initial AE/SAE report, the investigator is required to proactively follow each participant 
at subsequent visits/contacts.  All SAEs will be followed until resolution, stabilization, the event 
is otherwise explained, or the participant is lost to follow -up (as defined in Section 7.3).  
8.3.2. Physical Examinations 
At the s creening visit and at Weeks 8 and 52/EOT , a comprehensive physical examination 
should be conducted.  The comprehensive physical examination will include assessment(s) of the following organ or body systems:  skin; head, eyes, ears, nose, and throat; thyroid; lungs; cardiovascular system; abdomen (liver, spleen); extremities; and lymph nodes; as well as a brief 
neurological examination. 
During the study, participants will be assessed by [CONTACT_89199].  These assessments should be an evaluation as 
indicated by [CONTACT_89200], AEs, or other findings and documented on the AE eCRF. 
Physical examinations will be conducted at the timepoints listed in Tab le 3 and Table 4. 

Incyte Corporation   Page 60 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB  2019  
CONFIDENTIAL  8.3.3. Vital Signs  
Vital sign measurements (to be taken before blood collection for laboratory tests), include blood 
pressure, pulse, respi[INVESTIGATOR_697] , and body temperature.  Blood pressure and pulse wil l be taken 
with the participant in the sitting position after [ADDRESS_675447].  Height and w eight will also be 
assessed at s creening , Weeks 8, 24 and 52/ EOT .  Abnormal vital sign results identified after the 
first dose of study treatment constitute an AE if they are considered clinically meaningful, induce 
clinical signs or symptoms, or require concomitant therapy.  
8.3.4. Electrocardiograms  
A single 12- lead ECG will be obtai ned at screening  (12- lead ECG performed within 2 months 
before  baseline is acceptable) us ing an ECG machine that automatically calculates the heart rate 
and measures PR, QRS, QT, and QTc intervals.  All 12- lead ECGs will be performed with the 
participant in a recumbent or semirecumbent position after [ADDRESS_675448]. 
The decision to include or exclude a participant or withdraw a participant from the study treatment based on an ECG flagged as "Abnormal, Clinically Significant" is the responsibility of 
the investigator, in consultation with the sponsor's medical monitor, as appropriate.  Clinic ally 
notable abnormalities that are considered clinically significant in the judgment of the investigator are to be reported as AEs.  
8.3.5. Laboratory Assessments 
See Table [ADDRESS_675449] of clinical laboratory tests to be  performed and to the SoAs ( see Table 3 
and Table 4) for the timing and frequency.  A central laboratory will perform all clinical laboratory assessments for safety (ie, blood chemistries, hematology assessments, coagulation 
tests, endocrine function, and urinalysis), and will store the samples for PK and PD.  Additional testing may be required by [CONTACT_89202].  All Protocol-required 
laboratory ass essments must be conducted in accordance with the laboratory manual and the 
SoAs (see Table 3 and Table 4).  Information regarding collection, processing, and shippi[INVESTIGATOR_520705]. 
Clinically significant abnormal laboratory findings are those that are not associated with the 
underlying disease, unless judged by [CONTACT_520723]'s condition.  All laboratory tests with values considered clinically significantly 
abnormal during participation in the study, or within [ADDRESS_675450] dose of study treatment, should be repeated until the values return to normal or baseline or are no longer considered clinically significant by [CONTACT_10982].  
See Section  9.1 for information regarding laboratory abnormalities that should be recorded as an 
AE in the eCRF.  

Incyte Corporation   Page 64 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB  2019  
CONFIDENTIAL  8.8. Safety Follow -Up 
The safety follow -up period is the interval between the EOT visit and the scheduled follow-up 
visit, which should occur 30 (+ 7)  days after the EOT visit (or after the last dose of study 
drug/treatment if the EOT visit was not performed.  
Adverse events and SAEs must be reported up until at least [ADDRESS_675451] dose of study 
drug/treatment, the date of the follow- up visit, or until toxicities resolve, return to baseline, or are 
deemed irreversible, whichever is longer.  Reasonable efforts should be made to have the participant return for the follow-up visit and report any AEs that may occur during this period. 
9. ADVERSE EVENTS:  DEFINITIONS AND PROCEDURES FOR 
RECORDING, EVALUATING, FOLLOW-UP, AND REPORTING  
9.1. Definition of Adverse Event  
Adverse Event Definitio n 
• An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not 
considered drug- related.  
• An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment.  
Events Meeting  the Adverse Event Definition  
• Any safety assessments (eg, ECG, vital signs measurements), including those that worsen from baseline, considered clinically significant in the medical and scientific judgment of the investigator (ie, 
not related to progression of underlying disease). 
• Abnormal laboratory test results constitute an AE if they are considered clinically meaningful, induce clinical signs or symptoms, require co ncomitant therapy, or require changes in study drug.  Whenever 
possible, a diagnosis (eg, anemia, thrombocytopenia) should be recorded in the eCRF rather than the abnormal lab result (eg, low hemoglobin, platelet count decreased).  
• Exacerbation of a chronic or intermittent pre -existing condition including either an increase in 
frequency and/or intensity of the condition. 
• New conditions detected or diagnosed after study treatment administration even though they may have been present before the start of the st udy. 
• Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction. 
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study treatment or a concomitant medication.  Overdose per se will not be reported as an AE/SAE  unless it is an intentional 
overdose taken with possible suicidal/self -harming intent.  Such overdoses should be reported 
regardless of sequelae.  
• "Lack of efficacy " or " failure of expected pharmacological action " per se will not be reported as an AE 
or SA E.  Such instances will be captured in the efficacy assessments.  However, the signs, symptoms, 
and/or clinical sequelae resulting from lack of efficacy will be reported as an AE or SAE if they fulfil l 
the definition of an AE or SAE. 

Incyte Corporation   Page 65 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB  2019  
CONFIDENTIAL  Events NOT  Meeting the Adverse Event Definition  
• Any clinically significant abnormal laboratory findings or other abnormal safety assessments that are 
associated with the underlying disease, unless judged by [CONTACT_19988]'s condition. 
• The disease/disorder being studied or expected progression, signs, or symptoms of the disease/disorder 
being studied, unless more severe than expected for the participant 's condition or considered to be 
treatment -related by [CONTACT_093].  
• Efficacy endpoints as outlined in Section  2 will not be reported as AE/SAEs, specifically, any event 
that is related to disease progression.  Unblinded aggregated efficacy endpoint events and safety data will be m onitored to ensure the safety of the participants in the study.  Any suspected endpoint that 
upon review is not progression of the disease under study will be forwarded to Incyte Pharmacovigilance as a SAE within 24 hours of determination that the event is not progression of the 
disease under study. 
• Medical or surgical procedure (eg, endoscopy, appendectomy):  the condition that leads to the 
procedure is the AE if it occurred after signing informed consent /assent .  If present before entering the 
study, the condition should be captured as medical history. 
• Situations in which an untoward medical occurrence did not occur (social and/or convenience admission to a hospi[INVESTIGATOR_307]). 
• Anticipated day -to-day fluctuations of pre-existing disease(s) or condition(s) present or detected at the 
start of the study that do not worsen. 
9.2. Definition of Serious Adverse Event  
If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions 
are met (eg, hospi[INVESTIGATOR_1080]/symptoms of the disease u nder study, death due to 
progression of disease). 
A Serious Adverse Event is defined as any untoward medical occurrence that, at any dose:  
a.  Results in death  
b.  Is life -threatening  
The term 'life-threatening ' in the definition of 'serious' refers to an adve rse drug experience that places the 
participant, in the opi[INVESTIGATOR_89155], at immediate risk of death from the adverse experience as 
it occurred.  This does not include an adverse drug experience that, had it occurred in a more severe form, 
might have caused death . 
c.  Requires inpatient hospi[INVESTIGATOR_12993], hospi[INVESTIGATOR_19949] (usually involving at least an 
overnight stay) at the hospi[INVESTIGATOR_9235]/or treatment that would not have 
been appropriate in the physician's office or outpatient setting.  Complications that occur during 
hospi[INVESTIGATOR_1084].  If a complication prolongs hospi[INVESTIGATOR_9236], 
the event is serious.  When in doubt as to whether " hospi[INVESTIGATOR_059] " occurred or was necessary, the AE 
should be considered serious. 
Hospi[INVESTIGATOR_5187] a pre-existing condition that did not worsen from baseline is not 
considered an AE.  

Incyte Corporation   Page 66 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB  2019  
CONFIDENTIAL  d.  Results in persistent or significant disability/incapacity  
• The term disability means a substantial disruption of a person 's ability to conduct normal life functions. 
• This definition is not intended to include experiences of relatively mino r medical significance, such as 
uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (eg, sprained 
ankle), that may interfere with or prevent everyday life functions but do not constitute a substantial disruption. 
e.  Is a congenital anomaly/birth defect 
f. Other situations (Important Medical Event)  
An event that may not result in death, be immediately life -threatening, or require hospi[INVESTIGATOR_059], but may 
be considered serious when, based on appropriate medical judgment, the event may jeopardize the 
participant and may require medical or surgical intervention to prevent one of the outcomes listed in the 
above definition.   Examples of such events include invasive or malignant cancers (excluding the 
disease[s] under study in oncolog y protocols), intensive treatment in an emergency department or at home 
for allergic bronchospasm, blood dyscrasias, or convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency or drug abuse. 
9.3. Recording and Follow -Up of Adverse Events and/or Serious Adverse 
Events  
Adverse Event and Serious Adverse Event Recording  
• An AE/SAE that begins or worsens after informed consent /assent  is signed should be recorded on the 
Adverse Event Form in the eCRF.  Conditions that were present at the time informed consent/assent  
was given should be recorded on the Medical History Form in the eCRF.  
• When an AE/SAE occurs, it is the responsibility of the investigator to review all documentation (eg, 
hospi[INVESTIGATOR_1088], laboratory reports, and diagnos tics reports) related to the event.  
• The investigator (or delegate) will then record all relevant AE/SAE information in the eCRF.  
• It is not  acceptable for the investigator to send photocopi[INVESTIGATOR_10914] 's medical records in lieu 
of completing the AE eCRF page.  
• There may be instances when copi[INVESTIGATOR_63475].  In this case, all participant identifiers, with the exception of the participant number, will be redacted on the copi[INVESTIGATOR_346590]. 
• The investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or 
other clinical information.  Whenever possible, the diagnosis (not the individual signs/symptoms) will be documented as the AE/SAE.  When a clear diagnosis cannot be identified, each sign or symptom 
should be reported as a separate AE/SAE.  
To the extent possible, each AE/SAE should be evaluated to determine: 
• The severity grade (CTCAE v4.03 Grade 1 to 5).  See below for further instructions on the asses sment 
of intensity.  
• Whether there is at least a reasonable possibility that the AE is related to the study treatment:  suspected 
(yes) or not suspected (no).  See below for further instructions on the assessment of causality.  
• The start and end dates, unless unresolved at final follow-up. 
• The action taken with regard to study drug as a result of the AE/SAE(s). 
• The event outcome (eg, not recovered/not resolved, recovered/resolved, recovering/resolving, 
recovered/resolved with sequelae, fatal, unknown). 

Incyte Corporation   Page 67 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB  2019  
CONFIDENTIAL  • The se riousness, as per the SAE definition provided in Section  9.2. 
• The action taken with regard to the event.  Note:   If an AE is treated with a concomitant medication or 
nondrug therapy, this action should be recorded on Adverse Event Form and the treatment should be 
specified on the appropriate eCRF (eg, Prior/Concomitant Medications, Procedures and Non- Drug 
Therapy). 
Assessment of Intensity  
The severity of AEs will be assessed using CTCAE v4.03 Grades 1 through 5.  If an event is not classified by [CONTACT_3989], the severity of the AE will be graded according to the scale below to estimate the 
grade of severity:  
The investigator will make an assessment of intensity for each AE and SAE reported during the study and 
assign it to 1 of the following categories:  
• Grade 1:   Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment 
not indicated. 
• Grade 2:   Moderate; minimal, local, or noninvasive treatment indicated; limiting age appropriate 
activitie s of daily living.  
• Grade 3:   Severe or medical significant but not immediately life -threatening; hospi[INVESTIGATOR_8942]; disabling; limiting self -care activities of daily living.  
• Grade 4:   Life -threatening consequences ; urgent treatment indicated. 
• Grade 5:   Fatal.  
Assessment of Causality  
• The investigator is obligated to assess the relationship between study treatment and each occurrence of each AE/SAE.   
• A "reasonable possibility " of a relationship conveys that there are facts, evidence, and/or arguments to 
suggest a causal relationship, rather than that a relationship cannot be ruled out.  
• The investigator will use clinical judgment to determine the relationship.  
• The investigator will also consult the RSI in the IB and/or Product Information, for marketed products, in his/her assessment.  
• Alternative causes, such as underlying disease(s), concomitant therapy, and other risk factors, as well as 
the temporal relationship of the event to study treatment administration, will be considered and investigated.  
• For each AE/SAE, the investigator must  document in the medical notes that he/she has reviewed the 
AE/SAE and has provided an assessment of causality.  
• With regard to assessing causality of SAEs:  
− There may be situations in which an SAE has occurred and the investigator has minimal information 
to include in the initial report.  However, the causality assessment is one of the criteria used when determining regulatory reporting requirements.  Therefore, it is very important that the 
investigator always make an assessment of causality for every event before the initial transmission of the SAE.  
− The investigator may change his/her opi[INVESTIGATOR_9242] -up information and send a 
follow-up SAE report with the updated causality assessment.  

Incyte Corporation   Page 68 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB  2019  
CONFIDENTIAL  Follow -Up of Adverse Events and Serious Adverse Events  
• The investigator is obligated to perform or arrange for the conduct of supplemental measurements 
and/or evaluations as medically indicated or as requested by [CONTACT_22854]/or 
causality of the AE or SAE as fully as possible.  This may include additional laboratory tests or 
investigations, histopathological examinations, or consultation with other health care professionals. 
• If a participant dies during participation in the study or during a recognized follow-up period, the investigator will provide the sponsor with a copy of any postmortem findings including histopathology.   
• New or updated information will be recorded in the originally completed eCRF. 
• Any updated SAE data will be submitted to the sponsor (or designee) within 24 hours of receipt of the information. 
• Once an AE is detected, it should be followed until it has resolved or until it is judged to be permanent; assessment should be made at each visit (or more frequently if necessary) of any changes in severity, 
the suspected relationship to the study drug, the interventions required to treat the event, and the 
outcome. 
• When the severity of an AE changes over time for a reporting period (eg, between v isits), each change 
in severity will be reported as a separate AE until the event resolves.  
9.4. Reporting of Serious Adverse Events  
All SAEs, regardless of suspected causality (eg, relationship to study drug or study 
procedure[s]), occurring after the partici pant has signed the ICF /assent  through the last study 
visit or 30 (+ 7) days after the last dose of study drug, whichever occurs later, must be reported 
to the sponsor (or designee) within 24 hours of learning of its occurrence, unless otherwise 
specified by [CONTACT_89191].  The investigator will submit any updated SAE data to the sponsor (or 
designee) within 24 hours of it being available. 
Investigators are not obligated to actively seek AE or SAE information after conclusion of the 
study participation.  How ever, if the investigator learns of any SAE, including a death, at any 
time after a participant has been discharged from the study, and he/she considers the event to be 
reasonably related to the study treatment or study participation, the investigator must notify the 
sponsor (or designee) within 24 hours of becoming aware of the event. 
After the initial AE/SAE report, the investigator is required to proactively follow each participant 
at subsequent visits/contacts.  All SAEs will be followed until resolutio n, stabilization, the event 
is otherwise explained, or the participant is lost to f ollow-up (as defined in Section 7.3).  
Prompt notification by [CONTACT_11012] a SAE is essential so that legal obligations and ethical responsibilities towards the safety of participants and the safety of a study 
treatment under clinical investigation are met.  
If the SAE is not documented in the ruxolitinib cream IB for the study drug (new oc currence) 
and is thought to be related to the sponsor's study drug, the sponsor or its designee may urgently require further information from the investigator for reporting to health authorities.  The sponsor 
or its designee may need to issue an Investigat or Notification to inform all investigators involved 
in any study with the same drug that this SAE has been reported.  Suspected Unexpected Serious 
Adverse Reactions will be collected and reported to the competent authorities and relevant ethics 
committees  in accordance with Directive 2001/20/EC, or as per national regulatory requirements 
in participating countries.  

Incyte Corporation   Page 69 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB  2019  
CONFIDENTIAL  The sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study treatment under clinical investigation.  The 
sponsor will comply with country- specific regulatory requirements relating to safety reporting to 
the regulatory authority, IRB/IEC, and investigators. 
Investigator safet y reports must be prepared for suspected unexpected serious adverse reactions  
according to local regulatory requirements and sponsor policy and forwarded to investigators as 
necessary.  
An investigator who receives an investigator safety report describing a SAE or other specific 
safety information  (eg summary or listing of SAEs) from the sponsor will review and then file it 
along with the Investigator's Brochure and will notify the IRB/IEC, if appropriate according to 
local requirements.  
Serious Adverse Event Reporting  
• Information about all SAEs i s collected and recorded on the Adverse Event Form in the eCRF.  
• The investigator must also complete the Incyte Serious Adverse Event Report Form, in English.  Refer 
to the Incyte Reference Guide for Completing the Serious Adverse Event Report Form.  
• Facsimile or email transmission of the Serious Adverse Event Report Form is the preferred method to transmit this information to the PhV/designee (eg, C3i/Telerx).  The contact [CONTACT_89208]'s study- specific representatives is listed in the investigator manual provided to each site.  The 
original copy of the Serious Adverse Event Report Form and the confirmation sheet must be kept at the study site.  
• Follow-up information is recorded on an amended or new Serious Adverse Event Report Form, with an indic ation that it is follow -up to the previously reported SAE and the date of the original report.  The 
follow-up report should include information that was not provided on the previous Serious Adverse Event Report Form, such as the outcome of the event (eg, resolved or ongoing), treatment provided, 
action taken with study drug because of the SAE (eg, dose reduced, interrupted, or discontinued), or 
participant disposition (eg, continued or withdrew from study participation).  Each recurrence, 
complication, or progression of the original event should be reported as follow- up to that event, 
regardless of when it occurs.  
• In rare circumstances and in the absence of facsimile or computer equipment, notification by [CONTACT_13186] a copy of the Incyte Ser ious Adverse Event Report Form sent by [CONTACT_20022].  Initial notification via telephone does not replace the need for the investigator to complete and sign the Serious Adverse Event Report Form within the designated reporting time fra mes. 
• Contacts for SAE reporting can be found in the Study Manual.  
9.5. Emergency Unblinding of Treatment Assignment  
In a medical emergency during the study , if the investigator deems it necessary to determine 
optimal medical management of the participant, emer gency unblinding will be performed  
exclusively  by [CONTACT_079] [INVESTIGATOR_520706] .  The IRT system has  an option to select for "Emergency Code Break " action for a given 
participant.  After entering the 6- digit study drug tube number and verification of the unmasking 
information, the investigator/subinvestigator will proceed to either final confirmation or 
cancellation of the code break procedure.  

Incyte Corporation   Page 70 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB  2019  
CONFIDENTIAL  If a participant 's treatment assignment is unblinded, the sp onsor or its designee must be notified 
immediately by [CONTACT_520724]-up with an email. 
If an investigator, site personnel performing assessments, or participant is unblinded, the 
participant must be withdrawn from the study treatment, unless there are ethical reasons to have the participant remain on the study treatment.  In these cases, the investigator must obtain 
specific approval from the sponsor' s (or its designee 's) medical monitor for the participant to 
continue in the study. 
9.6. Pregnancy  
Pregnancy,  in and of itself, is not regarded as an AE unless there is suspi[INVESTIGATOR_147066] a contraceptive medication or method.  When a 
pregnancy has been confirmed in a participant during maternal or paternal exposure to study drug, the following procedures should be followed in order to ensure safety: 
• The study drug must be discontinued immediately. 
• The investigator must complete and submit the Incyte Clinical Trial Pregnancy Form 
to the sponsor or its designee within 24 hours  of learning of the pregnancy. 
Data on fetal outcome are collected for regulatory reporting and drug safety evaluation.  
Follow-up should be conducted for each pregnancy to determine outcome, including spontaneous or voluntary termination, det ails of the birth, and the presence or absence of any birth defects, 
congenital abnormalities, or maternal and/or newborn complications, by [CONTACT_352978]-baby [CONTACT_765].  Pregnancy should be recorded on a Clinical Trial Pregnancy Form and repo rted 
by [CONTACT_89211].  Pregnancy follow-up information should be 
recorded on the same form and should include an assessment of the possible causal relationship 
to the sponsor's study drug to any pregnancy outcome, as well as follow- up to the first well- baby 
[CONTACT_89212], whichever is later.  Refer to the Incyte 
Reference Guide for Completing the Clinical Trial Pregnancy Form.  
Any SAE occurring during pregnancy of a study participant must be recorded on the 
Serious Adverse Event Report Form and submitted to the sponsor or designee.  
Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital anomalies, or ectopic pregnancy) are considered SAEs (if occurring in the study participant) and must be reported as described in Section  9.4.  If an abnormal pregnancy outcome is reported in a 
study participant's partner, the event should be reported to the sponsor on the Cli nical Trial 
Pregnancy Form.  
9.7. Warnings and Precautions  
Special warnings or precautions for the study drug, derived from safety information collected by [CONTACT_3552], are presented in the IB.  Additional safety informatio n collected 
between IB updates will be communicated in the form of Investigator Notifications.  Any important new safety information should be discussed with the participant during the study, as necessary.  If new significant risks are identified, they wil l be added to the ICF /assent . 
There are no study -specific special warnings or precautions in this study.  

Incyte Corporation   Page [ADDRESS_675452] compla ints associated with other 
study material will be reported directly to the respective manufacturer.  
The investigator or his/her designee is responsible for reporting a complete description of the product complaint via email or other written communication to the sponsor contact [CONTACT_147111].  Any AE associated with a product 
complaint should be recorded as described in Section 9.3. 
If the investigator is asked to return the product for investigation, he/she will return a copy of the 
product complaint communication with the product. 
10. STATISTICS  
10.1. Sample Size Determination  
Approximately 600 participants will be randomized 2:2:1 to ruxolitinib 0.75% BID, 1.5% BID, 
or vehicle and stratified by [CONTACT_393611] (2, 3) and region (North America or other).  The sample size calculation is based on the Fisher exact test for the statistical comparison on the primary 
efficacy endpoint.  The Fisher exact test is used to provide a cons ervative evaluation of statistical 
power, and it is accurate when there is a small expected number  of responders in the vehicle 
group.  Based on the results from a Phase 2, randomized, dose- ranging study  (INCB  [ZIP_CODE]-206), 
the IGA -TS at Week 8 is assumed to  be 45% and 30% for active arms (1.5% BID and 0.75% 
BID, respectively) versus 10% for placebo.  Using a 2-sided alpha of 0.025, the sample size will 
have > 95% power to detect a difference between each of the 2 active treatment groups versus 
vehicle.  In addition to provide adequate power for efficacy variables, the sample size is 
determined to provide an adequate database for safety evaluation.  
10.2. Populations for Analysis  
Table 10 presents the populations for analysis. 

Incyte Corporation   Page 72 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB  2019  
CONFIDENTIAL  Table 10: Populations for Analysis 
Population Description  
ITT The ITT population includes all randomized participants.  Treatment groups for this 
population will be defined according to the treatment assignment at randomization. 
PP The PP population includes randomized participants who are considered to be sufficiently compliant with the Protocol.  
Safety  The safety population includes all participants who applied at least [ADDRESS_675453] 1  dose 
of ruxolitinib 0.75% or 1.5 % cream during the LTS pe riod.  All analyses for the 
LTS period will be conducted with the LTS evaluable population. 
PK/ 
pharmacodynamic 
evaluable  The PK/pharmacodynamic evaluable population includes participants who applied 
at least [ADDRESS_675454] will review data listings of participant 
administration and sample records to identify participants to be excluded from the 
analysis.  
10.3. Type I Error Control  
A graphical procedure with gatekeepi[INVESTIGATOR_393590].  The underlying procedure is derived using the methodology 
developed in Bretz et al ( 2009).  This method will guarantee a strong control of the family -wise 
error rate.  
Two families of 8 elementary hypotheses tests are grouped according to treatment comparison between each active dose group to vehicle, where 
• Family 1 (1.5% BID vs vehicle): 
− H11:  proportion of participants who achieve IGA- TS; 
− H12:  proportion of participants who achieve EASI-75; 
− H13:  proportion of participants with a ≥ 4-grade improvement in Itch NRS over 
baseline;  
− H14:  proportion of participants with a clinically meaningful improvement in the 
PROMIS Sleep  Disturbance score.  
• Family 2 (0.75% BID vs vehicle):  
− H21:  proportion of participants who achieve IGA -TS; 
− H22:  proportion of participants who achieve EASI-75; 
− H23:  proportion of participants with a ≥ 4-grade improvement in Itch NRS over 
baseline;  
− H24:  proportion of participants with a clinically meaningful improvement in the PROMIS Sleep Disturbance score.  

Incyte Corporation   Page 74 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB  2019  
CONFIDENTIAL  The difference in IGA-T S rates (ruxolitinib cream vs vehicle) at Week 8 will also be computed.  
The 95% confidence interval for the difference will be computed based on a large- sample normal 
approximation with continuity correction.  All nonresponders in the VC  treatment period,  as well 
as all participant s who discontinue study treatment at any time before the timepoint of interest, or 
discontinue from the study for any reason, will be defined as nonresponders for the nonresponder 
imputation analysis.   Sensitivity analyses, including longitudinal logistic regression with 
repeated measurements and multiple imputation, may be performed.  In addition, a tippi[INVESTIGATOR_520707].  Subgroup analysis 
by [CONTACT_520725] ( eg, IGA, region, and age ) will be performed.  Deta ils will be provided 
in the Statistical Analysis Plan . 
10.4.2. Secondary Analysis 
Secondary efficacy analyses will be conducted in the ITT population.  If the primary objective is 
achieved, the statistical co mparisons for key secondary endpoints will be tested with the 
procedures specified in  Figure  4.  The endpoints will be analyzed using the similar method as 
specified in the primary analysis.  
All other secondary and exploratory efficacy variables will be summarized using descriptive 
statistics.  For categorical measurements, summary statistics will include sample size, frequency, 
and percentages.  Similar logistic regression models as specified in the primary and key 
secondary analysis will be used if applicable.  For continuous measurements, summary statistics 
will include sample size, mean, median, standard deviation, standard error of the mean, minimum, and maximum.  Continuous efficacy endpoints, including the actual measurement, 
change from baseline, and percentage change from baseline may also be analyzed by [CONTACT_207114] -effect model with repeat measurement.  
10.4.3. Safety Analyses 
A TEAE is any AE either reported for the first time or worsening of a pre- existing event after  
first dose of study drug.  Analysis of AEs will be limited to TEAEs, but data listings will include all AEs regardless of their timing to study drug administration.  Adverse events will be tabulated by [CONTACT_169108].  Severity of AEs will be based on the 
National Cancer Institute CTCAE v4.[ADDRESS_675455] a relationship to study drug will be 
considered to be treatment- related AEs.  If the investigator do es not specify the relationship of 
the AE to study drug, then the AE will be considered treatment- related.  The incidence of AEs 
and treatment -related AEs will be tabulated.  
The clinical laboratory data will be analyzed using summary statistics; no formal treatment group 
comparisons are planned.  Laboratory test values outside the normal range will be assessed for 
severity based on the normal ranges for the clinical reference laboratory.  The incidence of abnormal laboratory values and shift tables relative to baseline will be tabulated.  
Descriptive statistics and mean change from baseline will be determined for vital signs (blood pressure, pulse, respi[INVESTIGATOR_697], and body temperature) at each assessment time.  

Incyte Corporation   Page 76 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB  2019  
CONFIDENTIAL  11. SUPPORTING DOCUMENTATION AND OPERATIONAL  
CONSIDERATIONS  
11.1. Investigator Responsibilities  
• The Protocol, Protocol amendments, ICF /assent , IB, and other relevant documents 
(eg, advertisements) must be submitted to an IRB/IEC by [CONTACT_31846]/IEC  before the study is initiated . 
• The investigator is responsible for ensuring that the safety reports provided by [CONTACT_352981] , the 
policies and procedures established by [CONTACT_1201]/IEC, and institutional requirements. 
• Any amendments to the Protocol will require IRB/IEC approval before 
implementation of changes made to the study design, except for changes necessary to 
eliminate an immediate h azard to study participants. 
• The investigator will be responsible for the following: 
− Providing written summaries of the status of the study to the IRB/IEC annually or 
more frequently in accordance with the requirements, policies, and procedures 
established  by [CONTACT_1201]/IEC . 
− Notifying the IRB/IEC of SAEs or other significant safety findings as required by 
[CONTACT_1744]/IEC procedures. 
− Providing oversight of the conduct of the study at the site and adherence to GCP , 
IRB/IEC requirements, institutional requirements, and applicable laws and country- specific regulations . 
• Adhering to the Protocol as described in this document and agreeing that changes to the Protocol procedures, with the exception of medical emergencies, must be 
discussed and approved, first, by [CONTACT_89223], second, by [CONTACT_5040]/IEC.  Each investigator is responsible for enrolling participants who have met 
the specified eligibility criteria.  
• Retaining records in accordance with all local, national, and regulatory laws, but for a 
minimum perio d of at least [ADDRESS_675456] article for 
investiga tion to ensure the availability of study documentation should it become 
necessary for the sponsor or a regulatory authority to review. 
− The investigator must not destroy any records associated with the study without 
receiving approval from the sponsor.  The investigator must notify the sponsor or 
its designee in the event of accidental loss or destruction of any study records.  If the investigator leaves the institution where the study was conducted, the sponsor 
or its designee must be contact[CONTACT_89224]. 

Incyte Corporation   Page 77 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB  2019  
CONFIDENTIAL  − All eCRF data entered by [CONTACT_779] (including audit trail), as well as computer 
hardware and software (for accessing the data), will be maintained or made 
available at the site in compliance with applicable record retentio n regulations.  
The sponsor will retain the original eCRF data and audit trail.  
11.2. Data Management  
Data management will be performed in a validated EDC system.  The investigator will be provided with access to an EDC system so that an eCRF can be completed for each participant.  
The site will be provided eCRF completion guidelines for instructions on data entry in the eCRF.  
The study monitor will reference the Monitoring Plan in order to ensure that each issue identified 
is appropriately documented, reported, and resolved in a timely manner in accordance with the plan's requirements.  
The sponsor (or designee) will be responsible for: 
• The data management of this study including quality checking of the data. 
• Ensuring that study monitors perform ongoing source dat a verification to confirm that 
data entered into the e CRF by [CONTACT_1191], complete, and 
verifiable from source documents; that the safety and rights of participants are being protected; and that the study is being conducted in ac cordance with the currently 
approved protocol and any other study agreements, ICH GCP, and all applicable regulatory requirements. 
The investigator will be responsible for: 
• Ensuring participant data relating to the study is recorded in the eCRF unless 
transmitted to the sponsor or designee electronically (eg, laboratory data, diary data) 
or as otherwise specified in the Protocol.  The investigator is responsible for verifying 
that data entries are accurate and correct by [CONTACT_520726].  
• Maintaining accurate documentation (source data) that supports the information 
entered in the eCRF.  
− Source documents provide evidence for the existence of the participant and substantiate the integrity of the data collected.  Source documents ar e filed at the 
investigator 's site.  
− Data reported on the CRF or entered in the eCRF that are transcribed from source 
documents must be consistent with the source documents or the discrepancies 
must be explained.  The investigator may need to request previous medical 
records or transfer records, depending on the study.  Also, current medical records must be available.  

Incyte Corporation   Page 78 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB  2019  
CONFIDENTIAL  • Permitting study -related monitoring, sponsor audits, IRB/IEC review, and regulatory 
inspections by [CONTACT_89225]. 
− Monitoring:  Qualified representatives of the sponsor or its designee, study 
monitors, will monitor the study according to a predetermined plan.  The investigator must allow the study monitors to review any study ma terials and 
participant records at each monitoring visit.  
− Auditing:  Qualified representatives of the sponsor or its designee may audit the clinical study site and study data to evaluate compliance with the Protocol, 
applicable local clinical study regulat ions, and overall study conduct.  The 
investigator must allow the auditors to review original source records and study documentation for all participants. 
− Regulatory inspection:  Regulatory authorities may conduct an inspection of the 
study and the site at  any time during the development of an investigational 
product.  The investigator and staff are expected to cooperate with the inspectors 
and allow access to all source documents supporting the eCRFs and other study-related documents.  The investigator mus t immediately notify the sponsor 
when contact[CONTACT_169109]. 
11.3. Data Privacy and Confidentiality of Study Records  
The investigator and the sponsor or its designee must adhere to applicable data prot ection  laws 
and regulations.  The investigator and the sponsor or its designee are responsible for ensuring that sensitive personal information is handled in accordance with local data protection laws  (including, but not limited to , HIPAA  and GDPR ).  Appropriate consent for collection,  use, and 
disclosure and/or transfer (if applicable) of personal information must be obtained in accordance with local data protection laws . 
Participant names will not be supplied to the sponsor or its designee.  Only the par ticipant 
number will be recorded in the eCRF; if the participant's name [CONTACT_75502] (eg laboratory report), it must be obliterated on the copy of the document to be supplied to the sponsor or its designee.  Study findings stored on a computer will be stored in accordance with 
appropriate technical and organizational measures as required by [CONTACT_89227].  
Records and documents, including signed ICFs /assents , pertaining to the conduct of this study 
must be retained by [CONTACT_41176] 30 years after study completion unless local regulations 
or institutional policies require a longer retention period.  No records may be destroyed during 
the retention period without the written approval of the sponsor.  No records may be transf erred 
to another location or party without written notification to the sponsor. 

Incyte Corporation   Page 79 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB  2019  
CONFIDENTIAL  11.4. Financial Disclosure  
Before study initiation, all clinical investigators participating in clinical studies participant  to 
FDA Regulation Title 21 CFR Part 54 – Financial Disclo sure by [CONTACT_6230] (ie, 
"covered studies ") are required to submit a completed Clinical Investigator Financial Disclosure 
form that sufficiently details any financial interests and arrangements that apply .  For the purpose 
of this regulation, "c linical investigator " is defined as any investigator or subinvestigator who is 
directly involved in the treatment or evaluation of research participants, including the spouse and 
each dependent child of the clinical investigator or subinvestigator.  These requirements apply to both US and foreign clinical investigators conducting covered clinical studies. 
Any new clinical investigators added to the covered clinical study during its conduct must also 
submit a completed Investigator Financial Disclosure Form.  During a covered clinical study, any changes to the financial information previously reported by a clinical investigator must be 
reported to the sponsor or its designee.  At the conclusion of the covered clinical study, the 
clinical investigators will be  reminded of their obligations.  In the event that the clinical 
investigator is not reminded, they nevertheless will remain obligated to report to the sponsor or 
its designee any changes to the financial information previously reported, as well as any chan ges 
in their financial information for a period of 1 year after completion of the covered clinical study. 
11.5. Publication Policy  
By [CONTACT_89228], the investigator and his/her institution agree that the results of the 
study may be used by [CONTACT_456], Incyte Corporation for the purposes of national and 
international registration, publication, and information for medical and pharmaceutical 
professionals.  Study results will be published in accordance with applicable local and national regulations.  If necessary, the authorities will be notified of the investigator's name, address, 
qualifications, and extent of involvement.  The terms regarding the publication of study results 
are contained in the agreement signed with the sponsor or its designee.  A signed agreement will 
be retained by [CONTACT_3552]. 
The results of this study may be published or presented at scientific meetings.  If this is foreseen, 
the investigator agrees to submit all manuscripts or abstracts to the sponsor before submission.  This allows the sponsor to protect proprietary information and to provide comments. 
The sponsor will comply with the requirements for publication of study results.  In accordance 
with standard editorial and ethical practice, the sponsor will gene rally support publication of 
multicenter studies only in their entirety and not as individual site data.  In this case, a 
coordinating investigator [INVESTIGATOR_12992]. 
Authorship will be determined in line with International Committee o f Medical Journal Editors 
authorship requirements. 

Incyte Corporation   Page [ADDRESS_675457] been collected and a study -site closure visit has been performed. 
The investigator may initiate study -site closure at any time, provided there is r easonable cause 
and sufficient notice is given in advance of the intended termination. 
Reasons for the early closure of a study site by [CONTACT_11004]: 
• Failure of the investigator to comply with the protocol, the requirements of the IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines. 
• Inadequate recruitment of participants by [CONTACT_093] . 
• Discontinuation of further study treatment  development. 

Incyte Corporation   Page 81 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB  2019  
CONFIDENTIAL  12. REFERENCES  
Akdis CA, Adkis M, Bie ber T, et al. Diagnosis and treatment of atopic dermatitis in children and 
adults: European Academy of Allergology and Clinical Immunology/American Academy of 
Allergy, Asthma and Immunology/PRACTALL Consensus Report. J Allergy Clin Immunol 
2006;118:152-169. 
Beck LA, Thaçi D, Hamilton JD, et al. Dupi[INVESTIGATOR_161407] -to-severe 
atopic dermatitis. N Engl J Med 2014;371:130-139. Bissonnette R, Papp KA, Poulin Y, et al. Topi[INVESTIGATOR_166509]: a phase IIa 
randomized trial. Br J Dermatol 2016;175:902-911. 
Bretz F, Maurer W, Brannath W, Posch M. A graphical approach to sequentially rejective 
multiple test procedures. Stat Med 2009;28:586-604. 
Buysse DJ, Yu L, Moul DE. Development and validation of patient-reported outcome me asures 
for sleep disturbance and sleep -related impairments. Sleep 2010;33:781-792. 
Charman CR, Venn AJ, Williams HC. The patient- oriented eczema measure: development and 
initial validation of a new tool for measuring atopic eczema severity from the patients' 
perspective. Arch Dermatol 2004;140:1513-1519. 
Clinical Trial Facilitation Group. Recommendations related to contraception and pregnancy 
testing in clinical trials. 2014. http://www.hma.eu/fileadmin/dateien/  
Human_Medicines/01-About_HMA/Working_Groups/CTFG/2014_09_HMA_CTFG_ Contraception.pdf. Accessed October 2, 2017. 
Dupi[INVESTIGATOR_12460]
® (dupi[INVESTIGATOR_12458]) [prescribing information]. Regeneron Pharmaceuticals, Inc.; 2017. 
Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic 
dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol 2014;70:338-351. 
Ellis CN, Drake LA, Prendergast MM, et al. Cost of atopic dermatitis and eczema in the United 
States. J Am Acad Dermatol 2002;46:361-370. 
Eucrisa
® (crisaborole) [prescribing information]. [COMPANY_007] Inc.; 2016. 
EuroQol Research Foundation. EQ-5D-5L. 2017. https://euroqol.org/eq-5d- instruments/eq -5d-5l-
about/. Accessed July 17, 2018. Finlay AY, Khan GK. Dermat ology Life Quality Index (DLQI) -- a simple practical measur e for 
routine clinical use. Clin Exp Dermatol 1994;19:210-216. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl 
(Stockh) 1980;92:44-47. 
Hanifin JM, Reed ML, Eczema Prevalence and Impact Working Group. A population- based 
survey of eczema prevalence in the [LOCATION_002]. Dermatitis 2007;18:82-91. 

Incyte Corporation   Page 82 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB  2019  
CONFIDENTIAL  Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and 
severity index (EASI): assessment of reliability in atopic dermatitis EASI Evaluator Group. Exp 
Dermatol 2001;10:11-18. 
Harrop J, Chinn S, Verlato G , et al. Eczema, atopy and allergen exposure in adults: a 
population-based study. Clin Exp Allergy 2007;37:526-535. 
Hay RJ, Johns NE, Williams HC, et al. The global burden of skin disease in 2010: an analysis of 
the prevalence and impact of skin conditions. J Invest Dermatol 2014;134:1527-1534. 
Hijnen D, De Bruin- Weller M, Oosting B, et al. Serum thymus and activation -regulated 
chemokine (TARC) and cutaneous T cell -attracting chemokine (CTACK) levels in allergic 
diseases: TARC and CTACK are disease- specific markers for atopic dermatitis. J Allergy Clin 
Immunol 2004;113:334-340. 
Hurst H, Bolton J. Assessing the clinical significance of change scores recorded on subjective 
outcome measures. J Manipulative Physiol Ther 2004;27:26-35. 
Kakinuma T, Nakamura K, Wakugawa M, et al. Thymus and activation-regulated chemokine in 
atopic dermatitis: serum thymus and activation -regulated chemokine level is closely related with 
disease activity. J Allergy Clin Immunol 2 001;107:535-541. 
Leshem YA, Hajar T, Hanifin JM, Simpson EL. What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study. Br J Dermatol 
2015;172:1353-1357. 
Levy LL, Urban J, King BA. Treatment of recalcitrant atopic dermatitis with the oral Janus 
kinase inhibitor tofacitinib citrate. J Am Acad Dermatol 2015;73:395-399. 
Mehta CR, Patel NR. Exact logistic regression: theory and examples. Stat Med 1995;14:2143-
2160. 
Michel M, L'Heureux N, Auger FA, Germain L. From newborn to adult: phenotypic and 
functional properties of skin equivalent and human skin as a function of donor age. J Cell Physiol 1997;171:179-189. 
Moreno AS, McPhee R, Arruda LK, Howell MD. Targeting the T helper 2 inflammatory axis in 
atopic dermatis. Int Arch Allergy Immunol 2016;171:71-80. 
Oakley A. SCORAD. 2009. https://www.dermnetnz.org/topi[INVESTIGATOR_1102]/scorad/. Accessed November 1, 
2018. 
Oetjen LK, Mack MR, Feng J, et al. Sensory neurons co- opt classical immune signaling 
pathways to mediate c hronic itch. Cell 2017;171:217-228. 
Papi[INVESTIGATOR_3694] A, Strowd C. Atopic dermatitis: a review of topi[INVESTIGATOR_393592]. Drugs Context 
2018;7:212521. 
Punwani N, Scherle P, Flores R, et al. Preliminary clinical activity of a topi[INVESTIGATOR_190048]1/2 inhibitor 
in the treatment of psoriasis. J Am Acad Dermatol 2012;67:658-664. 
Purv is D. Guidelines for the diagnosis and assessment of eczema. 2014. 
https://www.dermnetnz.org/topi[INVESTIGATOR_1102]/guidelines- for-the-diagnosis- and-assessment -of-eczema/ . 
Accessed July 17, 2018. 

Incyte Corporation   Page 83 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB  2019  
CONFIDENTIAL  Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and 
activity impairment instrument. PharmacoEconomics 1993;4:353-365. 
Rönmark EP, Ekerljung L, Lötvall J , et al. Eczema among adults: prevalence, risk factors and 
relation to airway dis eases. Results from a large-scale population survey in Sweden. Br J 
Dermatol 2012;166:1301-1308. Ruxolitinib  Cream Investigator's Brochure. Wilmington, DE: Incyte Corporation. 
Spergel JM. Epi[INVESTIGATOR_190057]. Immunol Allergy 
Clin North Am 2010;30:269-280. 
Thaçi D, Simpson, EL, Beck LA, et al. Efficacy and safety of dupi[INVESTIGATOR_73248]- to-severe atopic dermatitis inadequately controlled by [CONTACT_12523][INVESTIGATOR_12969]: a 
randomised, placebo-controlled, dose- ranging phase 2b trial. Lancet 2016;387:40-52. 
Vestergaard C, Bang K, Gesser B, Yoneyama H, Matsushima K, Larsen CG. A Th2 chemokine, TARC, produced by [CONTACT_393628]+CCR4 + lymphocytes into lesional atopic dermatitis skin. J Invest Dermatol 200 0;115: 640-646. 
Vinding GR , Zarchi K, Ibler KS, Miller IM, Ellervik C, Jemec GB . Is adult atopic eczema more 
common than we think? - A population-based study in Danish adults. Acta Derm Venereol 2014;94;480-482. 

Incyte Corporation   Page 84 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB  2019  
CONFIDENTIAL  APPENDIX A. INFORMATION REGARDING EFFECTIVENESS OF 
CONTRACEPTIVE METHODS  
For male participants in the study:  
Male participants should use a condom from screening through [ADDRESS_675458] had a vasectomy qualify as having met the requirement for a 
highly effective birth control method. 
For female participants in the study:  
Precautions to avoid pregnancy should be followed until the end of safety follow -up period 
(30 [+7]  days after EOT) . 
The following methods that can achieve a failure rate of less than 1% per year when used consistently and correctly are considered as highly effective birth control methods: 
• Combined (estrogen and progestogen containing) hormonal contraception associated with 
inhibition of ovulation 
− oral 
− intravaginal  
− transdermal  
• Progestogen -only hormonal contraception associated with inhibition of ovulation 
− oral 
− injectable  
− implantablea 
• Intrauterine devicea 
• Intrauterine hormone- releasing systema 
• Bilateral tubal occlusiona 
• Vasect omized partnerab 
• Sexual abstinencec 
a Contraception m ethods that in the context of this guidance are considered to have low user dependency.  
b Vasectomized partner is a highly effective method of avoiding pregnancy provided that partner is the sole sexual 
partner of the woman of childbearing potential study participant and that the vasectomized partner has received 
medical assessment of the surgical success.  
c In the context of this guidance, sexual abstinence is considered a highly effective method only if defined as 
refraining from heterosexual intercourse during the entire period of risk associated with the study treatments.  The 
reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the participant.  
Source:  Clinical Trial Facilitation Group 2014 . 

Incyte Corporation   Page 85 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB  2019  
CONFIDENTIAL  APPENDIX B.  PROTOCOL AMENDMENT SUMMARY OF CHANGES  
Document  Date  
Amendment (Version ) 1: 22 JAN 2019 
Amendment (Version) 2:  13 FEB 2019 
Amendment 2 (13 FEB 2019)  
Overall Rational for the Amendment:  
The primary purpose of this amendment is to incorporate revisions requested by [CONTACT_393629] (VHP). 
1. Section 1, Protocol Summary (Table 4, Schedule of Activities :  Long -Term Safety 
Extension Period ); Section 8.3.3, Vital Signs 
Description of change:   Updated to indicate that height and weight are assessed at 
screening  and Weeks 8 , 24, and 52/ EOT . 
Rationale for change:   To address VHP request. 
2. Section 5.1, Inclusion Criteria  
Description of change:   Fixed a n umber formatting error for inclusion criterion 7. 
Rationale for change:   To correct . 
3. Section 6.1, Study Treatment Administered 
Description of change:   Added text to clarify treatment application process for the 
participant.  
Rationale for change:   To clarify.  
4. Section 6.6.3, Prohibited Medications and Procedures 
Description of change:   Deleted text  to clarify that allergen immunotherapi[INVESTIGATOR_520708]. 
Rationale for change:   To address VHP request. 
5. Section 9.5, Emergency Unblinding of Treatment Assignment  
Description of change:   Revised  to be clear that emergency unblinding is permitted at 
any stage of the entire study and not only during the VC period. 
Rationale for change:   To address VHP request. 

Incyte Corporation   Page 86 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB  2019  
CONFIDENTIAL  6. Section 8.3.4, Electrocardiograms  
Description of change:   Deleted text  to clarify the electrocardiogram process.  
Rationale for chan ge:  To clarify . 
7. Incorporation of administrative changes .  Other minor, administrative changes have 
been incorporated throughout the Protocol and are noted in the redline version of the 
amendment.  

Incyte Corporation   Page 88 of 88 
Protocol INCB [ZIP_CODE]- 304 Am 2  Version 2 13 FEB  2019  
CONFIDENTIAL  6. Section 5.2, Exclusion Criteria (Criterion 3b) 
Description of change:  Text added to limit the history of malignan cy to within the past 
5 years.  
Rationale for change:   To address VHP request and to provide additional detail 
regarding what was  intended by [CONTACT_393630].  
7. Section 5.2, Exclusion Criteria (Criteria 13 and 14) Description of change:  Addition of criteria to exclude participants who have been 
committed to a mental institution due to an order from judicial or administrative 
authorities.  In addition, participants should be excluded if they are employees or 
dependents of the sponsor or investigator. 
Rational for change:  To address VHP request. 
8. Section 6.6.3, Prohibited Medications and Procedures 
Description of change:  Text added to clarify that allergen immunotherapi[INVESTIGATOR_393594] a stable and established regimen.  
Rationale for change:  Additional clarification for the use allergen immunotherapi[INVESTIGATOR_014].  
9. Section 9.5, Emergency Unblinding of Treatment Assignment 
Description of change:   Text revised to indicate that an emergency unblinding procedure 
is possible during the entire clinical study and that the sponsor must be notified by 
[CONTACT_97266] a follow- up email.  
Rationale for change:  To address VHP request. 
10. Section 10.1, Sample Size Determination Description of change:   Updated to include additional information about the Fisher exact 
test and a Phase 2 study reference for the IGA -TS values at Week 8.    
Rationale for change:  To address VHP request.  
11. Section 10.4.1, Primary Analysis Description of change:  Text added to clarify  the analysis to be performed . 
Rationale for change: To address VHP request. 
12. Appendix A, Information Regarding Effectiveness of Contraceptive Methods  
Description of change:   Removed the footnote regarding hormonal contraception and 
the section containing acceptable birth control with failur e rate of more than 1% per year.  
Rationale for change:  To address VHP request.  
13. Incorporation of administrative changes.  Other minor, administrative changes have 
been incorporated throughout the Protocol and are noted in the redline version of the 
amendment. 
